Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets

Highlights

- Single-cell-omics demonstrate megakaryocyte-biased hematopoiesis in myelofibrosis (MF)
- Megakaryocyte progenitors (MkPs) show high expression of a fibrosis signature in MF
- MkPs are heterogeneous in MF with aberrant metabolic and inflammatory signatures
- Targeting aberrant surface G6B expression may selectively ablate the MF clone

In Brief

Myelofibrosis (MF) is characterized by increased numbers of morphologically abnormal megakaryocytes (Mks). Single-cell RNA sequencing of >120,000 hematopoietic stem and progenitor cells demonstrated Mk-biased hematopoiesis across clinical and molecular MF subgroups. Mk progenitors were heterogeneous, with distinct expression of inflammatory mediators. Aberrant surface G6B expression on MF stem and progenitors could allow selective immunotherapeutic targeting of the MF clone.

Authors

Bethan Psaila, Guanlin Wang, Alba Rodriguez-Meira, ..., David M. Bodine, Supat Thongjuea, Adam J. Mead

Correspondence

bethan.psaila@ndcls.ox.ac.uk (B.P.), supat.thongjuea@imm.ox.ac.uk (S.T.), adam.mead@imm.ox.ac.uk (A.J.M.)
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets

Bethan Psaila, 1,2,3,4,14,* Guanlin Wang, 1,2,3,5,14 Alba Rodriguez-Meira, 1,2,3,5 Rong Li, 1,2,3 Elisabeth F. Heuston, 4 Lauren Murphy, 1,2,3 Daniel Yee, 6 Ian S. Hitchcock, 8 Nikolaos Sousos, 1,2,3 Jennifer O’Sullivan, 1,2,3 Stacie Anderson, 7 Yotis A. Senis, 6 Olga K. Weinberg, 6 Monica L. Calichio, 6 NIH Intramural Sequencing Center, 10 Deena Iskander, 2,3,13 David M. Bodine, 4 Supat Thongjuea, 3,5,* and Adam J. Mead 1,2,3,15,*

1Haematopoietic Stem Cell Biology Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, Oxford OX3 9DS, UK
2MRC Molecular Haematology Unit, MRC WIMM, University of Oxford, Oxford OX3 9DS, UK
3NIHR Biomedical Research Centre, University of Oxford, Oxford OX4 2PG, UK
4Hematopoiesis Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-4442, USA
5MRC WIMM Centre for Computational Biology, MRC WIMM, University of Oxford, Oxford OX3 9DS, UK
6York Biomedical Research Institute and Department of Biology, University of York, Heslington, York YO10 5DD, UK
7NHGRI Flow Cytometry Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-4442, USA
8Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-S 1255, Etablissement Français du Sang Grand Est, Strasbourg 67065, France
9Department of Pathology, Boston Children’s Hospital, Boston, MA 02115, USA
10National Institutes of Health, Bethesda MD 20892-442, USA
11Centre for Haematology, Hammersmith Hospital, Imperial College of Medicine, London W12 OHS, UK
12Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK
13Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK
14These authors contributed equally
15Lead Contact
*Correspondence: bethan.psaila@ndcls.ox.ac.uk (B.P.), supat.thongjuea@imm.ox.ac.uk (S.T.), adam.mead@imm.ox.ac.uk (A.J.M.)
https://doi.org/10.1016/j.molcel.2020.04.008

SUMMARY

Myelofibrosis is a severe myeloproliferative neoplasm characterized by increased numbers of abnormal bone marrow megakaryocytes that induce fibrosis, destroying the hematopoietic microenvironment. To determine the cellular and molecular basis for aberrant megakaryopoiesis in myelofibrosis, we performed single-cell transcriptome profiling of 135,929 CD34+ lineage hematopoietic stem and progenitor cells (HSPCs), single-cell proteomics, genomics, and functional assays. We identified a bias toward megakaryocyte differentiation apparent from early multipotent stem cells in myelofibrosis and associated aberrant molecular signatures. A sub-fraction of myelofibrosis megakaryocyte progenitors (MkPs) are transcriptionally similar to healthy-donor MkPs, but the majority are disease specific, with distinct populations expressing fibrosis- and proliferation-associated genes. Mutant-clone HSPCs have increased expression of megakaryocyte-associated genes compared to wild-type HSPCs, and we provide early validation of G6B as a potential immunotherapy target. Our study paves the way for selective targeting of the myelofibrosis clone and illustrates the power of single-cell multi-omics to discover tumor-specific therapeutic targets and mediators of tissue fibrosis.

INTRODUCTION

Advances in single-cell technologies have recently provided new insights into the cellular and molecular diversity and pathological mechanisms underlying many diseases, including cancers, pre-malignant and non-malignant conditions (Baslan and Hicks, 2017; Owen et al., 2018; Parikh et al., 2019). Parallel interrogation of mutation status and the transcriptome at a single-cell level provides an unprecedented opportunity to identify cancer-cell-specific targets (Giustacchini et al., 2017; Nam et al., 2019; Rodriguez-Meira et al., 2019). Single-cell resolution also uniquely enables the identification of rare cell types and analysis of combinatorial patterns of gene expression, both of which are necessary to reconstruct differentiation trajectories and to accurately define cellular heterogeneity between populations, such as normal and malignant tissues, as well as to identify the mediators of
interactions between different cell types. For example, pathological fibrosis underlies many prevalent diseases, including cancer, where fibrosis is well recognized to be important for disease progression and metastasis (Chandler et al., 2019; Cox and Erler, 2014). It is broadly proposed that pro-fibrotic mediators secreted by cancer cells and infiltrating immune cells activate non-malignant stromal cells, such as myofibroblasts, to deposit collagen fibrosis (Cox and Erler, 2014). However, an understanding of the specific cellular populations that mediate fibrosis in a given disease model, their molecular features, and the cellular pathways through which they are generated is necessary for these cells to be therapeutically targeted.

Myelofibrosis is the most severe of the “myeloproliferative neoplasms” (MPNs), a group of heterogeneous disorders that result from somatic mutations in hematopoietic stem and progenitor cells (HSPCs) affecting Janus Kinase (JAK) signaling. The most common driver mutation is JAK2V617F, occurring in ~60% of myelofibrosis patients (James et al., 2005), with mutations affecting calreticulin (mutCALR) found in the majority of other patients (Klampfl et al., 2013; Nangalia et al., 2013). Myelofibrosis can occur as a primary disorder (PMF) or develop secondary to the other MPNs polycythemia vera (post-polycythemia vera myelofibrosis [PPV-MF]) or essential thrombocythaemia (post-essential thrombocythaemia myelofibroses [PET-MF]). Myelofibrosis is characterized by a progressive bone marrow fibrosis that destroys the hematopoietic microenvironment, resulting in the cardinal disease features of cytopenias, mobilization of HSPCs to peripheral blood, extramedullary hematopoiesis, and a high propensity for leukemia. Survival is typically 5–10 years from diagnosis and is not substantially improved by currently available drug therapies (O’Sullivan and Harrison, 2018). Megakaryocytes, the platelet-producing cells in the bone marrow, are dramatically increased in number in myelofibrosis and are one of the key cellular drivers of the destructive bone marrow remodelling by releasing excess pro-fibrotic cytokines and growth factors (Ciurea et al., 2007; Eliades et al., 2011; Martyre et al., 1997; Wen et al., 2015). In normal hematopoiesis, megakaryocyte progenitors (MkPs) have a low proliferation rate, typically undergoing less than 8 cell divisions before mitotic arrest and the onset of polypliodization (Paulus et al., 2004), and megakaryocytes are relatively rare cells in healthy bone marrow.

The cellular and molecular pathways that give rise to the dramatically increased megakaryocyte numbers and megakaryocyte dysfunction leading to tissue fibrosis are unclear. In traditional models of normal hematopoiesis, megakaryocytes are said to arise from a bipotent progenitor shared with the erythro/ megakaryocyte-erythroid progenitor (MEP) (Akashi et al., 2000; Debili et al., 1996; Kondo et al., 1997; Manz et al., 2002; Pang et al., 2005; Psaila et al., 2016; Psaila and Mead, 2019; Sanada et al., 2016). It is broadly proposed that pro-fibrotic mediators secreted by cancer cells and infiltrating immune cells activate non-malignant stromal cells, such as myofibroblasts, to deposit collagen fibrosis (Cox and Erler, 2014). However, an understanding of the specific cellular populations that mediate fibrosis in a given disease model, their molecular features, and the cellular pathways through which they are generated is necessary for these cells to be therapeutically targeted.

Myelofibrosis is the most severe of the “myeloproliferative neoplasms” (MPNs), a group of heterogeneous disorders that result from somatic mutations in hematopoietic stem and progenitor cells (HSPCs) affecting Janus Kinase (JAK) signaling. The most common driver mutation is JAK2V617F, occurring in ~60% of myelofibrosis patients (James et al., 2005), with mutations affecting calreticulin (mutCALR) found in the majority of other patients (Klampfl et al., 2013; Nangalia et al., 2013). Myelofibrosis can occur as a primary disorder (PMF) or develop secondary to the other MPNs polycythemia vera (post-polycythemia vera myelofibrosis [PPV-MF]) or essential thrombocythaemia (post-essential thrombocythaemia myelofibroses [PET-MF]). Myelofibrosis is characterized by a progressive bone marrow fibrosis that destroys the hematopoietic microenvironment, resulting in the cardinal disease features of cytopenias, mobilization of HSPCs to peripheral blood, extramedullary hematopoiesis, and a high propensity for leukemia. Survival is typically 5–10 years from diagnosis and is not substantially improved by currently available drug therapies (O’Sullivan and Harrison, 2018). Megakaryocytes, the platelet-producing cells in the bone marrow, are dramatically increased in number in myelofibrosis and are one of the key cellular drivers of the destructive bone marrow remodelling by releasing excess pro-fibrotic cytokines and growth factors (Ciurea et al., 2007; Eliades et al., 2011; Martyre et al., 1997; Wen et al., 2015). In normal hematopoiesis, megakaryocyte progenitors (MkPs) have a low proliferation rate, typically undergoing less than 8 cell divisions before mitotic arrest and the onset of polypliodization (Paulus et al., 2004), and megakaryocytes are relatively rare cells in healthy bone marrow.

The cellular and molecular pathways that give rise to the dramatically increased megakaryocyte numbers and megakaryocyte dysfunction leading to tissue fibrosis are unclear. In traditional models of normal hematopoiesis, megakaryocytes are said to arise from a bipotent progenitor shared with the erythro/ megakaryocyte-erythroid progenitor (MEP) (Akashi et al., 2000; Debili et al., 1996; Kondo et al., 1997; Manz et al., 2002; Pang et al., 2005; Psaila et al., 2016; Psaila and Mead, 2019; Sanada et al., 2016). It is broadly proposed that pro-fibrotic mediators secreted by cancer cells and infiltrating immune cells activate non-malignant stromal cells, such as myofibroblasts, to deposit collagen fibrosis (Cox and Erler, 2014). However, an understanding of the specific cellular populations that mediate fibrosis in a given disease model, their molecular features, and the cellular pathways through which they are generated is necessary for these cells to be therapeutically targeted.
The CD41+ fraction of human CD38-positive CD34+ lin− CD45RA+ HSCs contains megakaryocyte-biased progenitors with significant erythroid differentiation potential as well as multi-potent MkP (Miyawaki et al., 2017; Psaila et al., 2016). However, the phenotype of CD41+ cells within the CD38-negative HSC/ MPP compartment has not previously been defined. We, therefore, sought to determine whether the CD41+ HSCs and MPP cells isolated from healthy donors retained a capacity for multi-lineage differentiation or were lineage-committed MkP, CD34+ Lin− CD38+ CD45RA+ CD90+ CD41+ (CD41+ HSC), CD34+ Lin− CD38− CD45RA− CD90− CD41− (CD41−MPP), and CD34+Lin− CD38− CD45RA− CD90− CD41+ (CD41+MPP) cells were isolated by fluorescence-activated cell sorting (FACS) for liquid culture differentiation assays. When stimulated with thrombopoietic cytokines, CD41+ HSC/MPP cells showed accelerated megakaryocyte differentiation with a substantially higher proportion of...
cells expressing the mature megakaryocyte surface antigen CD42, a large cell size, and proplatelet extensions at early time points as compared to CD41– HSCs and MPPs (Figure 1C). In parallel megakaryocyte, erythroid, and myeloid differentiation assays, CD41+ HSC/MPP showed a similar potential for CD11b/CD14+ myeloid differentiation and a superior potential for CD71+/glycophorin A erythroid differentiation than CD41– fractions (Figure 1D).

In comparison to those from healthy donors, CD41– HSC/MPP cells from myelofibrosis patients showed a megakaryocyte versus erythroid differentiation bias (Figure 1E), in keeping with the clinical phenotype of myelofibrosis patients in which excessive megakaryocyte numbers occur in parallel with anemia. In single-cell clonogenic assays supportive of myeloid and erythroid (but not megakaryocytic) colony formation (methocult), CD41– and CD41+ fractions of HSCs and MPPs gave rise to expected colony frequencies with myelofibrosis CD41– HSC/MPP showing a bias toward myeloid versus erythroid colonies (Figure S1B). Together, these results support that in myelofibrosis, HSPCs are biased toward megakaryocyte-lineage differentiation from the earliest stem cell compartment, even before expression of canonical megakaryocytic markers.

High-Throughput scRNA-Seq Identifies a Distinct Pathway for Megakaryocyte Differentiation in Myelofibrosis

To identify the cellular and molecular basis for megakaryocyte-biased hematopoiesis in myelofibrosis without bias from pre-selected cell surface antigens, high-throughput scRNA-seq was performed on 135,929 individual CD34+ lin– HSPCs from patients with JAK2V617F+ or mutCALR+ myelofibrosis (93,157 cells, n = 15) according to World Health Organization (WHO) criteria (Arber et al., 2016) and age-matched healthy donors (42,772 cells, n = 6) by using the 10x Genomics Chromium platform (Table S2). Filtering, quality control and doublet exclusion was performed (Table S3). Healthy donor control and myelofibrosis cells were aggregated and individual donor effect was regressed out, following which no batch effect remained (Figure S1C). A contaminating population of plasmacytic dendritic cells was identified and removed from all downstream analysis (Figure S1D). Following these steps, 120,196 cells (82,255 myelofibrosis and 37,941 control cells) were used for downstream analyses (Table S3).

Dimensionality reduction and unsupervised clustering were performed using a uniform manifold approximation and projection (UMAP) method combined with the Louvain community-detection clustering method to enable identification of distinct cell populations while preserving inter-cluster relationships (Becht et al., 2018) (Figure 2A). A total of 8 clusters were identified and manually annotated by correlation of differentially expressed genes for each cluster with reference marker genes for each lineage (Buenrostro et al., 2018; Hua et al., 2019; Pellin et al., 2019; Popescu et al., 2019) (Figure 2A; Figure S1E; Table S4). “Lineage signature” gene sets were established by an analysis of published datasets (Buenrostro et al., 2018; Hua et al., 2019; Pellin et al., 2019; Popescu et al., 2019) to identify genes selectively expressed in erythroid, myeloid, lymphoid, and megakaryocyte lineage progenitors and uncommitted...
HSPCs and were superimposed on the UMAPs (Figure 2B; Figures S1F and S2; Table S5).

Most HSPCs expressing megakaryocyte signature genes were derived from myelofibrosis patients with very few from healthy donors (Figures 2B–2D; Figure S1F). The average proportion of HSPCs with a megakaryocyte gene signature was ~5% for individual myelofibrosis patients, 11-fold higher than for healthy donors (4.96% [range, 0.52%–19.81%] for myelofibrosis versus 0.44% [range, 0%–1.51%] for controls, p < 0.05). Down-sampling the myelofibrosis cells to create a dataset with equal numbers of control and myelofibrosis HSPCs confirmed that over 93% of HSPCs in the MkP cluster originated from myelofibrosis donors, whereas less than 10% lymphoid progenitor cells were from myelofibrosis patients. The fractions of myeloid and erythroid progenitor cells were not significantly different (Figures 2D and S1F), supporting a strong megakaryocyte bias and reduction in lymphoid differentiation in myelofibrosis.

To study differentiation trajectories, cells were ordered in gene expression space by using force-directed graphs (FDG), and the lineage signature gene scores were superimposed on the graphs (Figures 3A–3D). The HSPC signature highlighted cells at the origin of the trajectory, and erythroid, megakaryocyte, myeloid, and lymphoid trajectories formed distinct paths, with MPP cells primarily located in intermediate positions in the trajectories (gray cells, Figures 3A–3D, left plots; Figure S3). Expression of megakaryocyte signature genes (purple) was observed along a prominent distinct trajectory originating from the apex of the HSPC cluster in the FDG trajectory in myelofibrosis patients (Figures 3B and 3D). In contrast, in healthy donors, very few MkP cells were observed in a distinct differentiation trajectory (Figures 3C and 3D). Notably, most of these cells derived from two of the six healthy donors (donors ID06 and ID09; Figure S3C). Together with functional data (Figure 1), these data support a model in which a direct route for MkP production from HSPCs cells were observed in a distinct differentiation trajectory (Figures 3B and 3D). Additional genes not previously implicated as regulators of megakaryocyte versus erythroid differentiation showed striking differential expression between the erythroid and megakaryocyte trajectories, including YBX1, HMGA1, PLEK, SOX4, and MYC (Figures 4B and 4C), suggesting additional targets for strategies to specifically inhibit pathological megakaryopoiesis while preserving erythropoiesis in myelofibrosis patients.

### Identifying Mediators of Megakaryocyte-Induced Fibrosis

To evaluate the pathological role of the expanded MkPs in driving bone marrow fibrosis, we next examined potential mediators of fibrosis among HSPCs. Fibrosis regulators were identified from previously published datasets studying lung and liver fibrosis as well as bone marrow fibrosis (Allen et al., 2017; Blackman et al., 2013; Corvol et al., 2015; Gu et al., 2009; Mondet et al., 2015; Mushiroda et al., 2008; Noth et al., 2013; Ulveling et al., 2016; Wattacheril et al., 2017; Wright et al., 2011). Genes detected at expression levels over 1 (using log-transformed unique molecular identifier [UMI]) in our HSPC dataset were selected for a “fibrosis signature” gene score (Table S5). Superimposition of this score on the UMAP for all healthy donor and myelofibrosis HSPCs clearly highlighted the MkP cluster cells as being the key regulators of fibrosis among all HSPCs (Figure 5A).

Healthy donor and myelofibrosis MkPs were then extracted for further analyses (Figure S4A). Gene set enrichment analysis (GSEA) of all expressed genes pre-ranked according to their differential expression between myelofibrosis and control MkP showed significant enrichment of metabolic (e.g., oxidative phosphorylation and fatty acid metabolism) and inflammatory pathways (e.g., transforming growth factor α [TNF-α] signaling and interferon gamma response) in myelofibrosis MkPs (Figure 5B). A subset of myelofibrosis MkPs (cluster center 6) showed a similar gene expression profile to control MkPs (Figures 5C and 5D). These cells had a high expression of key inflammatory mediators previously implicated in myelofibrosis, including PDGFA, CCL5, and CXCL5 (Figures 5C and 5D) (Elad et al., 2011; Malar et al., 2018; Mascalasinas et al., 2017). However, the majority of myelofibrosis MkPs had a unique gene expression profile with overall upregulation of genes normally expressed at low levels in healthy donor MkPs (Figures 5C and S4B). This finding suggests that megakaryocyte-induced fibrosis in myelofibrosis is due to both expansion of a population of megakaryocytes analogous to those in normal bone marrow as well as the generation of an aberrant population, an observation that would not have been possible without analysis at the single-cell resolution.

### Myelofibrosis MkPs Demonstrate Molecular Heterogeneity with Differential Expression of Proliferation and Fibrosis Genes

To further dissect cellular and molecular heterogeneity among myelofibrosis MkP, unsupervised clustering using Louvain
community detection was performed on myelofibrosis MkP. Nine sub-clusters were identified with distinct expression of fibrosis and proliferation-associated genes (Figures 5D, 5E, and S5A). Genes encoding key mediators of fibrosis (TGFB1, TNF, and LTBP1, which encodes a protein that targets the latent form of transforming growth factor beta [TGF-β] and contributes to its activation; Robertson et al., 2015), were most highly expressed in MkP clusters 6–8, whereas MkP clusters 2 and 8

Figure 3. A Distinct Trajectory for Megakaryocyte Differentiation Is Dramatically Expanded in Myelofibrosis
(A–D) Force-directed graphs (FDGs) for aggregate of all control + myelofibrosis cells (A), myelofibrosis only (B), control only (C), and control + down-sampled myelofibrosis dataset (D). In (D), the left graph shows lineage signature gene score and in the right graph cells are colored according to the donor type (healthy donors, blue; myelofibrosis, red). Gene expression trajectories are visualized by superimposing the expression scores of lineage signature gene sets on FDG. Grey cells represent uncommitted HSPCs or cells with expression of more than 1 lineage signature. See also Figures S2 and S3 and Table S5.
showed the highest expression of the proliferation marker MKI67 and a G2M gene signature (Figures 5E and S5B). AURKA was selectively expressed in two clusters, with particularly high expression in the minor cluster 8 (Figure 5E). This is of interest as AURKA is the target for alisertib (MLN8237), which was recently demonstrated to promote megakaryocyte polyploidization and ameliorate the myelofibrosis phenotype in mouse models (Wen et al., 2015), with some efficacy also in patients with myelofibrosis (Gangat et al., 2019).

Normal megakaryocytes have a low proliferation index, and healthy donor MkPs showed low expression of the proliferation marker MKI67. By contrast, MKI67 was strongly expressed in the majority of myelofibrosis MkPs and the MkP cluster showed the highest expression of MKI67 among all myelofibrosis HSPC clusters (Figure S5C) as well as an enrichment of a G2M checkpoint gene signature (Figure S5B; Table S5), suggesting that increased proliferation of MkPs may contribute to the pathological accumulation of megakaryocytes in myelofibrosis, in addition to megakaryocyte-biased hematopoiesis.

Identifying Myelofibrosis Clone-Specific Cell Surface Targets
Increased expression of megakaryocyte genes in the myelofibrosis aggregate was noted not just within the MkP cluster but also within clusters of uncommitted HSPCs and other lineage-affiliated clusters (Figure 6A). This included intracellular proteins (PF4 and VWF) and also cell surface antigens (ITGA2B [CD41] and MPIG6B [G6B]). Increased expression of MPIG6B, encoding the G6B protein, was particularly striking (Figure 6A). G6B is an immunoreceptor tyrosine-based inhibition motif (ITIM)-containing inhibitory receptor, considered to be exclusively expressed on mature megakaryocytes in normal hematopoiesis (Coxon et al., 2017; Senis et al., 2007). As the majority of healthy donor CD34+ lin− HSPCs did not express megakaryocyte genes and because mature megakaryocytes normally lose expression of CD34 during differentiation (Tomer, 2004), we hypothesized that aberrant co-expression of stem and progenitor and megakaryocyte surface antigens may enable the selective identification of myelofibrosis clone-derived HSPCs.

Figure 4. Molecular Regulators That May Drive Aberrant Megakaryocyte Differentiation in Myelofibrosis
(A) Left: FDG generated using Scanpy of all myelofibrosis CD34+ lin− cells, showing unsupervised clusters based on Louvain community-detection method. Right: pseudotime for the differentiation path from HSCs superimposed on the FDG plot.
(B) Expression of selected transcription factor genes over pseudotime from HSC → HSPC2 → megakaryocyte and HSC → HSPC2 → Ery differentiation paths.
(C) Expression of 6 genes that are differentially expressed between the erythroid and megakaryocyte trajectories over pseudotime.
Patients with myelofibrosis have distinct genetic subclones of HSPCs, including residual wild-type clones (non-mutated) as well as clones with co-mutations in addition to driver mutations (JAK2V617F or mutCALR). To determine whether the increase in the expression of megakaryocyte-associated genes was specific to mutant clone-derived HSPCs or due to cell-extrinsic signals affecting both mutated and un-mutated HSPCs, data generated by combined high-sensitivity mutational analysis and parallel transcriptome profiling (TARGET-seq; Rodríguez-Meira et al., 2019) were analyzed. A total of 2,734 cells were examined—678 healthy donor cells plus 2,056 myelofibrosis cells (388 JAK2 wild type and 1,668 JAK2V617F mutated). Expression of megakaryocyte genes, in particular G6B, was significantly higher in JAK2V617F-mutated HSPCs than in either wild-type cells from the same patients or in wild-type cells from healthy donors (32% versus 22.9% versus 14.7%, respectively; p < 0.001; Figure 6B). Wild-type cells from myelofibrosis patients also showed increased frequency of G6B expression, albeit to a lower degree than JAK2V617F-positive cells, in keeping with cell-extrinsic signals also contributing to this aberrant megakaryocyte differentiation (Figure 6B).

The high-throughput TARGET-seq and 10x Chromium datasets included all CD34+ lin- cells. Expression levels of G6B were also increased specifically in individual JAK2 mutant CD38- early stem and progenitor cells (HSC/MPP; Figure 6C) identified from the index sorting data of the TARGET-seq cells, and in 100-cell “mini-bulk” preparations of FACS-isolated immunophenotypic CD34+ Lin- CD38- CD45RA- CD90+ HSCs, CD34+ Lin- CD38- CD45RA- CD90- MPPs, and CD41+ HSC/MPPs (Figure 6D).

To examine where cells with specific genotypes fell on the HSPC trajectory, the datasets of myelofibrosis HSPCs analyzed by high-throughput 10x Genomics and TARGET-seq were integrated using Harmony (Korsunsky et al., 2019) (Figure S6A). FDG trajectory analysis showed that both wild-type and mutant progenitors fell in all 3 of the lineage progenitor trajectories (myeloid, erythroid, and megakaryocyte; Figure S6A). However, a higher proportion of the cells in the megakaryocyte and myeloid trajectories were mutant versus wild type than the erythroid trajectory (Figure S6A, right plot). In two patients with 3+ co-mutations in addition to the driver JAK2V617F mutation, the increase in G6B was observed in all genetic sub-clones detected (Figure S6B).

Expression of the Cell Surface G6B Protein Selectively Identifies Mutant Clone-Derived HSPCs in Myelofibrosis

High-throughput, single-cell proteomics by mass cytometry time of flight (CyTOF) was performed to simultaneously measure 20 surface proteins in multiple samples in parallel by using barcode multiplexing (Figure 7A; Table S7). G6B was consistently detected at substantially higher levels in patients with primary and secondary myelofibrosis and with JAK2V617F and mutCALR driver mutations than in healthy donors (Figures 7A and 7B). In addition, high cell surface G6B expression was also detected exclusively on JAK2V617F-mutated MPN cell lines (HEL and SET2) and not on the other leukemia cell lines, namely K562, HL60, JURKAT, and MAR-IMO, and HEK (human embryonic kidney) cells (Figure S7A). G6B expression was noted in both the CD41-positive and -negative cell fractions in myelofibrosis by FACS (Figure 7B, right plots).

To examine G6B expression in bone marrow megakaryocytes in situ, immunohistochemical staining was performed on trephine biopsy sections from healthy donors and patients with mutCALR and JAK2V617F+ myelofibrosis, confirming the expected expression on control megakaryocytes but with a dramatic increase in G6B+ cells in myelofibrosis (Figure 7C).

To confirm G6B as a potential marker of HSPCs derived from the malignant clone, G6B-positive and -negative cells were FACS-isolated from healthy donor and myelofibrosis patient MNcs and the expression of mutant versus wild-type JAK2 was determined by quantitative real-time PCR (Moliterno et al., 2006). Expression of mutant JAK2V617F relative to wild-type JAK2 was dramatically higher in G6B-positive cells (Figure 7D).

To validate that aberrant co-expression of G6B by mutant clone-derived HSPCs may be a potential strategy for immunotherapy, a tool bi-specific antibody was generated to target a stem and progenitor surface antigen (CD34) and G6B and labeled with a pH-sensitive cyanine Cypher5E dye that maximally fluoresces at an acidic pH following cellular internalization. Rapid internalization of the bi-specific by SET-2 cells (a JAK2V617F+ MPN cell line expressing both CD34 and G6B), as indicated by clear intracellular fluorescence, was observed (Figure 7E). Internalization was significantly reduced by two inhibitors of endocytosis, Dynasore (a GTPase inhibitor of dynamin) and Pitstop 2 (an inhibitor of the clathrin terminal domain). Internalization was also observed in CD34-negative, G6B+ HEL cells (Figure 7B) and not in G6B-negative cells nor with an isotype-control antibody, confirming that internalization was mediated by the G6B receptor. This strategy may have the potential to deliver therapeutic antibody conjugates directly to G6B+ mutant clone-derived cells. Together, these data identify G6B as a promising cell surface antigen worthy of further validation as enabling selective targeting of
Figure 6. Increased Expression of Megakaryocyte-Associated Genes in Myelofibrosis Is Not Restricted to the MF-MkP Cluster but Is Substantially Higher in Cells Derived from the JAK2V617F+ Mutant Clone

(A) Expression of intracellular (PF4 and VWF) and cell surface (ITGA2B [CD41] and G6B) megakaryocyte genes is not limited to myelofibrosis MkPs, particularly for G6B.

(legend continued on next page)
aberrant megakaryocytic differentiation and mutant clone-derived HSPCs in myelofibrosis.

**DISCUSSION**

Bone marrow transplant is currently the only potentially curative treatment for myelofibrosis but is associated with significant risk and most patients are ineligible due to age and comorbidities. The introduction of JAK inhibitors has led to significant improvement in symptomatic management, but most patients continue to experience substantial morbidity and a significant reduction in life expectancy. New approaches to treatment are urgently required. Megakaryocytes are well recognized as the key cellular drivers of disease pathogenesis (Malara et al., 2018); however, only one megakaryocyte-targeting therapy—alisertib, a specific inhibitor of aurora kinase—has been developed to date (Gangat et al., 2019; Wen et al., 2015). A major obstacle to identification of novel targets has been the inability to isolate megakaryocytes from patients for detailed study. In the present study, we reasoned that aberrant megakaryopoiesis in myelofibrosis is very likely to be caused by aberrant differentiation of HSPCs, rather than proliferation of mature megakaryocytes alone, and that this process might be amenable to therapeutic targeting to "turn off the supply." We, therefore, set out to characterize the distinct cellular and molecular features of megakaryocyte differentiation pathways in myelofibrosis by using a combination of single-cell approaches. We demonstrate a dramatic expansion of megakaryocyte differentiation from uncommitted stem and progenitor cells in JAK2V617F-driven hematopoiesis. Furthermore, we identify a number of molecular targets that may inhibit the abnormal megakaryocyte differentiation and potentially ablate mutant clone-derived HSPCs and MkPs.

Importantly, several key observations were only possible due to the single-cell-level resolution of study, highlighting the power of single-cell technologies in understanding disease pathology and in novel therapeutic target discovery. First, our data indicate that aberrant megakaryopoiesis in myelofibrosis is due to both a dramatic expansion of MkP with a similar transcriptional signature to healthy donor MkPs, as well as generation of a unique, aberrant MkP population. Second, by simultaneously interrogating the mutational status and the transcriptome of individual cells, we demonstrated that certain megakaryocyte surface antigens, in particular G6B, are markedly over-expressed in mutant clone-derived HSPCs compared with wild-type HSPCs from myelofibrosis patients or healthy donor HSPCs. This validates combinatorial targeting of stem cell (e.g., CD34) and megakaryocyte (e.g., G6B) surface antigens, e.g., with bi-specific antibody therapies as a potential strategy worthy of further investigation for selective ablation of the myelofibrosis clone. As none of the currently available treatments for MPNs reliably induce clonal remissions or substantially reduce fibrosis, this work sets the stage for immunotherapeutic targeting of aberrant hematopoiesis in myelofibrosis. Furthermore, the approach we have adopted and the resulting insights are highly relevant to other studies seeking to identify cancer-cell-specific drug targets and cancer-associated fibrosis in other malignancies, as well as non-malignant disorders of tissue fibrosis.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
  - Cell lines
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Banking and processing of human samples
  - Fluorescent activated cell sorting (FACS) staining, analysis and cell isolation
  - In vitro liquid culture differentiation assays
  - Cytospins and MGG
  - Methocult assay
  - High-throughput single-cell RNA-sequencing (10x Chromium)
  - TARGET-seq analysis
  - RNA sequencing of ‘mini-bulk’ HSPC populations
  - Antibody labeling with metal conjugates and mass cytometry (CyTOF)
  - G6B Immunohistochemistry
  - Sorting G6B+ and G6B- HSPCs for JAK2V617F qRT-PCR
  - CD34 x G6B bispecific antibody generation
  - Antibody internalization experiments
  - 10x Genomics single-cell RNA sequencing data preprocessing and integration
  - Dimensionality reduction, removal of individual donor effect and cell clustering
  - Lineage signature gene sets
  - Marker gene identification and cell type annotation
  - Down-sampling of myelofibrosis cells
  - MkP identification and sub-clustering analysis
  - Individual donor analysis

(B and C) Simultaneous targeted mutational profiling and RNA sequencing (TARGET-seq) of 2,734 individual CD34+ Lin- HSPCs (B) and CD38-negative stem cells (C) identified by index sorting data show higher expression of megakaryocyte-associated genes ITGA2B (CD41), VWF, SELP, and G6B in JAK2V617F-mutated (JAK2+) versus wild-type cells from the same patients (WT-p) or age-matched healthy donor control HSPCs (WT-HD). Fraction and % of cells in which gene expression were detected and are shown. The combined p value for Fisher’s exact test and Wilcoxon rank-sum test is shown (**p < 0.01, ***p ≤ 0.001). Points represent expression values for each single cell, and boxes represent median and quartiles for each group.

(D) G6B expression in bulk-sorted control and myelofibrosis immunophenotypic HSC (CD34+ Lin- CD38+ CD45RA- CD40-), MPP (CD34+ Lin- CD38+ CD45 RA- CD90+), and CD41+ HSC/MPP (CD34+ Lin- CD38-CD45RA- CD41+). TPM, transcripts per million. Chart shows mean ± SEM, n = 4 for controls and n = 3 for myelofibrosis; **p < 0.05, ***p ≤ 0.01. See also Figure S6.
**Figure 7. Expression of Cell Surface G6B, a Cell Surface Protein, Identifies Mutant Clone-Derived HSPCs in Myelofibrosis**

(A) Left: expression of 6 megakaryocyte markers from a panel of 20 HSPC and megakaryocyte cell surface antigens assayed by mass spectrometry time of flight (CyTOF) shows expression of G6B on CD34+ HSPCs from patients with primary myelofibrosis (PMF), post-essential thrombocythemia myelofibrosis (PET-MF), and post-polycythaemia vera myelofibrosis (PPV-MF) with either JAK2V617F (JAK2+) or calreticulin (mutCALR) driver mutations. Histograms show cell count (legend continued on next page)

(B) % CD34+ G6B+ Cells

(C) Control JAK2V617F+ MF CALRmut MF

(D) JAK2V617F expression relative to wild-type JAK2

(E) CD34 x G6B bispecific internalization by SET-2 cells

(legend continued on next page)
(C) Immunohistochemical staining for G6B (diaminobenzidine, DAB brown) of bone marrow biopsy sections from controls and myelofibrosis patients with

- Controls (N = 8); myelofibrosis (N = 11).

(E) Internalization of a CD34

JAK2

mut

JAK2V617F

and mut

JAK2V617F

G6B+ and G6B

versus 2.4% ± 1.0%; chart shows mean + SEM (left) and example plot (right) shown, illustrating expression in both CD41+ and negative cells. **p

3. Data shown using SET-2 cells, chart shows mean + SEM, ** - P < 0.01 n= 3. See also Figure S7.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.
molcel.2020.04.008.

ACKNOWLEDGMENTS

We thank all the patients who kindly donated samples; Dr. Sally-Ann Clark and others in the MRC WIMM Flow Cytometry facility; Dr. Michalina Mazurczyk in the Mass Spectrometry Facility and Dr. Neil Ashley in the MRC WIMM Single Cell Facility; Dr. Alice Young in the NHG Intramural Sequencing Center; the NHGRI Flow Cytometry facility; the University of York Imaging and Cytometry facility; and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). This work was funded by a Cancer Research UK Advanced Clinician Scientist Fellowship and CRUK Innovation Award; a Welcome Career Development Fellowship; an Academy of Medical Sciences Award and a L’Oreal-UNESCO Women in Science Award to B.P.; a Medical Research Council (MRC) Senior Clinical Fellowship, CRUK Early Detection Project Grant and CRUK Senior Cancer Research Fellowship to A.J.M.; Bloodwise and LAB282 (project grants to B.P. and A.J.M.); a Cancer Research UK DPhil Prize Studentship to A.R.-M.; a MRC John Fell Fund award and the MRC Molecular Haematology Unit core award to A.J.M.; and an MRC John Fell Fund award to B.P. and A.J.M. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health, or the NIH.

AUTHOR CONTRIBUTIONS

B.P. designed, performed, and analyzed experiments; performed bioinformatic analyses; and wrote the manuscript. G.W. participated in experimental planning and designed, developed, and performed bioinformatic analyses. A.R.-M. designed, performed, and analyzed TARGET-seq experiments and performed bioinformatic analyses. E.F.H. performed experiments and contributed to bioinformatic analyses. R.L., L.M., J.O., and N.S. performed experiments, processed samples, and analyzed data. S.A. performed experiments. Y.A.S. contributed the G6B antibody and interpreted data. D.Y. and I.S.H. performed and analyzed antibody internalization experiments. O.K.W., D.R., and M.L.C. performed the immunohistochemical staining and analyses. D.I. performed experiments and assisted with protocol development. D.M. contributed clinical samples and data interpretation. I.R. and D.M.B. helped to supervise the project. S.T. designed, developed, and supervised the computational data analysis and wrote the manuscript. A.J.M. supervised the project, designed experiments, interpreted data, and wrote the manuscript. All authors read and approved the submitted manuscript.

DECLARATION OF INTERESTS

The authors declare no relevant competing interests.

Received: May 20, 2019
Revised: February 4, 2020
Accepted: April 6, 2020
Published: May 7, 2020

SUPPORTING CITATIONS

The following reference appears in the Supplemental Information: Passamonti et al., 2019.

REFERENCES

Adolfsson, J., Mánson, R., Buza-Vidas, N., Hultquist, A., Liuba, K., Jensen, C.T., Bryder, D., Yang, L., Borge, O.J., Thoren, L.A., et al. (2009). Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 121, 295–306.

Albar, S., González-Blas, C.B., Moeremans, T., Huynh-Thu, V.A., Imrichova, H., Hulsemans, G., Rambow, F., Marine, J.C., Geurts, P., Aerts, J., et al. (2017). SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086.

Akashi, K., Traver, D., Miyamoto, T., and Weissman, I.L. (2000). A clonal common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197.

Allen, R.J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T.E., Oldham, J.M., Guillen-Guo, B., Ma, S.F., Okamoto, T., John, A.E., et al. (2017). Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir. Med. 5, 889–890.

Arber, D.A., Oriaz, A., Hassierian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M., and Vardiman, J.W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405.

Baslan, T., and Hicks, J. (2017). Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat. Rev. Cancer 17, 557–569.

Becht, E., McInnes, L., Healy, J., Dutertre, C.A., Kwok, I.W.H., Ng, L.G., Ginhoux, F., and Newell, E.W. (2018). Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38–44.

axis) by expression level (x axis). Right: viSNE dimensionality reduction plots on a representative control and myelofibrosis sample for CD9 and G6B, illustrating more substantial differential expression of G6B than CD9 in myelofibrosis versus control cells

(B) Flow cytometric analysis of G6B expression on CD34+ Lin- HSPCs showing significant increase in G6B+ cells in myelofibrosis (% GFP+ cells, 28.8% ± 5.5% versus ± 2.4% ± 1.0%); chart shows mean ± SEM (left) and example plot (right) shown, illustrating expression in both CD41+ and negative cells. **p ≤ 0.01 (t test).

Controls (N = 8); myelofibrosis (N = 11).

(C) Immunohistochemical staining for G6B (diaminobenzidine, DAB brown) of bone marrow biopsy sections from controls and myelofibrosis patients with JAK2V617F and mutCALR-positive myelofibrosis showing marked expansion of G6B+ megakaryocytes and progenitors in myelofibrosis.

(D) Mononuclear cells from healthy donors and patients with JAK2V617F+ myelofibrosis were combined and 50 cell “mini-bulk” replicates were sorted from the G6B+ and G6B- fractions for Taqman qRT-PCR to quantify expression of JAK2V617F mutated and wild-type JAK2. Chart shows JAK2V617F relative to wild-type JAK2 expression for all mini-bulks from 3 replicate experiments.

(E) Internalization of a CD34 × G6B bi-specific antibody and isotype control antibody conjugated to a pH-sensitive cyanine CypHer5E dye that fluoresces at an acidic pH following internalization. Left: representative images show clear intracellular fluorescence for CD34 × G6B bi-specific but not isotype control. Right: mean fluorescence intensity of cells measured by flow cytometry 30 min after addition of antibody with/without two endocytosis inhibitors, Dynasore and Pitstop 2. Data shown using SET-2 cells, chart shows mean ± SEM. ** - P < 0.01 n= 3. See also Figure S7.
Benz, C., Copley, M.R., Kent, D.G., Wohrer, S., Cortes, A., Aghaeepour, N., Ma, E., Mader, H., Rowe, K., Day, C., et al. (2012). Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell 10, 273–283.

Blackman, S.M., Commander, C.W., Watson, C., Arcara, K.M., Strug, L.J., Stonebraker, J.R., Wright, F.A., Rommens, J.M., Sun, L., Pace, R.G., et al. (2013). Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 62, 3627–3635.

Boulloux, F., Juban, G., Cohet, N., Buet, D., Guyot, B., Vainchenker, W., Louache, F., and Moré, F. (2008). EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. Blood 112, 576–584.

Brennecke, P., Anders, S., Kim, J.K., Kolodziejczyk, A.A., Zhang, X., Proserpio, V., Baying, B., Benes, V., Teichmann, S.A., Marioni, J.C., and Heisler, M.G. (2013). Accounting for technical noise in single-cell RNA-seq experiments. Nat. Methods 10, 1059–1065.

Buenrostro, J.D., Corces, M.R., Laos, C.A., Wu, B., Schea, A.N., Aryee, M.J., Majeti, R., Chang, H.Y., and Greenleaf, W.J. (2018). Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation. Cell 173, 1535–1548.e1516.

Carrelha, J., Meng, Y., Kettle, L.M., Luis, T.C., Norfo, R., Alcolea, V., Boukarabila, H., Grasso, F., Gambardella, A., Grover, A., et al. (2018). Hierarchically organized lineage-restricted fates of multipotent haematopoietic stem cells. Nature 554, 106–111.

Chandler, C., Liu, T., Buckanovich, R., and Coffman, L.G. (2019). The double edge sword of fibrosis in cancer. Transl. Res. 209, 55–67.

Ciurea, S.O., Merchant, D., Mahmud, N., Ishii, T., Zhao, Y., Hu, W., Bruno, E., Barosi, G., Xu, M., and Hoffman, R. (2007). Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110, 986–993.

Corvol, H., Blackman, S.M., Boele, P.Y., Gallins, P.J., Pace, R.G., Stonebraker, J.R., Accurso, F.J., Clement, A., Collaco, J.M., Dang, H., et al. (2015). Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat. Commun. 6, 8382.

Cox, T.R., and Erler, J.T. (2014). Molecular pathways: connecting fibrosis and solid tumor metastasis. Clin. Cancer Res. 20, 3637–3643.

Coxon, C.H., Geer, M.J., and Senis, Y.A. (2017). ITIM receptors: more than just sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 14, 105–111.

Clampit, T., Gisalinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milošević, D., Thém, N.C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013). Somatic mutations of caleretinin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379–2390.

Kondo, M., Weissman, I.L., and Akashi, K. (1997). Identification of clonal common lymphoid progenitors in mouse bone marrow. Cell 91, 661–672.

Kampfinga, H.H., Hageman, J., Vos, M.J., Kubota, H., Tanguay, R.M., Bruford, E.A., Cheetham, M.E., Chen, B., and Hightower, L.E. (2009). Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 14, 105–111.

Klampf, T., Gisalinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milošević, D., Thém, N.C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013). Somatic mutations of caleretinin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379–2390.

Kondo, M., Weissman, I.L., and Akashi, K. (1997). Identification of clonal common lymphoid progenitors in mouse bone marrow. Cell 91, 661–672.

Korsuksky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1298–1299.

Kotchek, N., Kuznetz, P.O., and Irish, J.M. (2010). Web-based analysis and publication of flow cytometry. Curr. Protoc. Cytom. 53, 10.17.1–10.17.24.

Lambert, S.A., Jolma, A., Campitelli, L.F., Das, P.K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T.R., and Weirauch, M.T. (2018). The Human Transcription Factors. Cell 72, 650–665.

Laurenti, E., and Göttgens, B. (2018). From haematopoietic stem cells to complex differentiation landscapes. Nature 553, 418–426.

Macia, E., Ehrlich, M., Massol, R., Bourcet, E., Brunner, C., and Kirchhausen, T. (2006). Dynasore, a cell-permeable inhibitor of dynamin. J. Biol. Chem. 281, 3407–3418.

Mascarenhas, J.O., Talpaz, M., Gupta, V., Foltz, L.M., Savona, M.R., Paquette, R., Verner, J., Verner, J., and Bieker, J.J. (2007). Novel role for EKLF in megakaryocyte lineage commitment. Blood 109, 1535–1548.e1516.

Mclnnnes, L., Healy, J., and Melville, J. (2018). UMAP: Uniform manifold approximation and projection for dimension reduction. arXiv, 1802.0342 https://arxiv.org/abs/1802.0342.
Miyawaki, K., Iwaaki, H., Jiromaru, T., Kusumoto, H., Yurino, A., Sugio, T., Uehara, Y., Odawara, J., Daitoku, S., Kunisaki, Y., et al. (2017). Identification of unipotent megakaryocyte progenitors in human hematopoiesis. Blood 129, 3332–3343.

Moliterno, A.R., Williams, D.M., Rogers, O., and Spivak, J.L. (2006). Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108, 3913–3915.

Mondet, J., Hussein, K., and Mossuz, P. (2015). Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest. Mediators Inflamm. 2015, 670580.

Mushiroda, T., Wattanapokayakit, S., Takahashi, A., Nukiwa, T., Kudoh, S., Ogura, T., Taniguchi, H., Kudo, M., Kamatani, N., and Nakamura, Y.; Pirfenidone Clinical Study Group (2008). A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J. Med. Genet. 45, 654–656.

Nakao, A., Yoshishama, M., and K ennochi, N. (2004). RGP: the Ribosomal Protein Gene Database. Nucleic Acids Res. 32, D168–D170.

Nam, A.S., Kim, K.T., Chalighe, R., Izzo, F., Ang, C., Taylor, J., Myers, R.M., Abu-Zeinah, G., Brand, R., O manas, N.D., et al. (2019). Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature 571, 355–360.

Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G., et al. (2013). Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391–2405.

Neth, I., Zhang, Y., Ma, S.F., Flores, C., Barber, M., Huang, Y., Broderick, S.M., Wade, M.S., Hysj, P., Scuriub, J., et al. (2013). Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir. Med. 1, 309–317.

Notta, F., Zandi, S., Takayama, N., Dobson, S., Gan, O.I., Wilson, G., Kaufmann, K.B., McLeod, J., Laurenti, E., Dunant, C.F., et al. (2016). Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science 351, aab2116.

O’Sullivan, J.M., and Harrison, C.N. (2018). Myelofibrosis: clinicopathologic features, prognosis, and management. Clin. Adv. Hematol. Oncol. 16, 121–131.

Owen, R.P., White, M.J., Severson, D.T., Braden, B., Bailey, A., Goldin, R., Wang, L.M., Ruiz-Puig, C., Maynard, N.D., Green, A., et al. (2018). Single cell RNA-seq reveals profound transcriptional similarity between Barrett’s oesophagus and oesophageal submucosal glands. Nat. Commun. 9, 4261.

Palig, C.G., Cheng, Q., Gillespie, S.A., Shannon, P., Mazurczyk, M., Nolaptiini, G., Price, N.D., Ranish, J.A., Morrissey, E., Higgs, D.R., and Brand, M. (2019). Single-Cell Proteomics Reveal that Quantitative Changes in Co-expressed Lineage-Specific Transcription Factors Determine Cell Fate. Cell Stem Cell 24, 812–820.e5.

Pang, L., Weiss, M.J., and Poncz, M. (2005). Megakaryocyte biology and related disorders. J. Clin. Invest. 115, 3332–3338.

Parikh, K., Antanaviciute, A., Fawkner-Corbett, D., Jagielowicz, M., Aulicino, A., Lander, A., Davis, S., Kinchen, J., Chen, H.H., Alham, N.K., et al. (2019). Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature 567, 45–55.

Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Marfelli, M., et al. (2010). A comprehensive single cell transcriptional landscape of human hematopoietic progenitors. Nat. Commun. 10, 2395.

Picelli, S., Faradini, O.R., Bjorklund, A.K., Winberg, G., Sagasser, S., and Sandberg, R. (2014). Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9, 171–181.

Popescu, D.M., Botting, R.A., Stephenson, E., Green, K., Webb, S., Jardine, L., Calderbank, E.F., Polanski, K., Goh, I., Efremova, M., et al. (2019). Decoding human fetal liver haematopoiesis. Nature 574, 365–371.

Psaila, B., and Mead, A.J. (2019). Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation. Blood 133, 1427–1435.

Psaila, B., Barkas, N., Iskander, D., Roy, A., Anderson, S., Ashley, N., Caputo, V.S., Lichtenberg, J., Nikiwa, T., Bodine, D.M., et al. (2016). Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. Genome Biol. 17, 83.

Ridgway, J.B., Presta, L.G., and Carter, P. (1996). “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617–621.

Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47.

Robertson, I.B., Horuguchi, M., Zilerberg, L., Dabovich, B., Hadijolova, K., and Tifkin, D.B. (2015). Latent TGF-β-binding proteins. Matrix Biol. 47, 44–53.

Roch, A., Trachsel, V., and Lutolf, M.P. (2015). Brief Report: Single-Cell Analysis Reveals Cell Division-Independent Emergence of Megakaryocytes From Phenotypic Hematopoietic Stem Cells. Stem Cell 33, 3152–3157.

Rodriguez-Fraticelli, A.E., Wolock, S.L., Weinreb, C.S., Panero, R., Patel, S.H., Jankovic, M., Sun, J., Calogero, R.A., Klein, A.M., and Camardo, F.D. (2018). Clonal analysis of lineage fate in native haematopoiesis. Nature 553, 212–216.

Rodriguez-Meira, A., Buck, G., Clark, S.A., Povinelli, B.J., Alves, J., Louka, E., McGowan, S., Hamblin, A., Soous, N., Barkas, N., et al. (2019). Unraveling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. Mol. Cell 73, 1292–1305.e8.

Sanada, C., Xavier-Ferrucio, J., Lu, Y.C., Min, E., Zhang, P.X., Zou, S., Kang, E., Zhang, M., Zerafati, G., Gallagher, P.G., and Krause, D.S. (2016). Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction. Blood 128, 923–933.

Sanjuan-Pla, A., Macaulay, I.C., Jensen, C.T., Wall, P.S., Luis, T.C., Mead, A., Moore, S., Carella, C., Matsuoka, S., Bouriez Jones, T., et al. (2013). Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 502, 232–236.

Senis, Y.A., Tomlinson, M.G., Garcia, A., Dumon, S., Heath, V.L., Herbert, J., Cobbold, S.P., Spalton, J.C., Ayman, S., Antrobus, R., et al. (2007). A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including Gbb-B, a novel immunoreceptor tyrosine-based inhibitory motif protein. Mol. Cell. Proteomics 6, 548–564.

Shin, J.Y., Hu, W., Naramura, M., and Park, C.Y. (2014). High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. J. Exp. Med. 211, 217–231.

Siripin, D., Kheolamai, P., U-Prayta, Y., Supokawee, A., Wattanapitch, M., Klincumhom, N., Laotwattamathorn, C., and Issaragrisil, S. (2015). Transdifferentiation of erythroblasts to megakaryocytes using FLJ1 and ERG transcription factors. Thromb. Haemost. 114, 593–602.

Tomer, A. (2004). Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood 104, 2722–2727.

Uveling, D., Le Clerc, S., Cobat, A., Labib, T., Noirel, J., Laville, V., Coulonjes, C., Carpenter, W., Nalpas, B., Heim, M.H., et al.; HEPAVIH ANRS CO13 Cohort Study Group; Swiss Hepatitis C Cohort Study Group; French ANRS HCV EP 26 Genoscan Study Group. (2016). A new 3p25 locus is
associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 64, 1462–1472.
Velten, L., Haas, S.F., Raffel, S., Blaszkiewicz, S., Islam, S., Hennig, B.P., Hirche, C., Lutz, C., Buss, E.C., Nowak, D., et al. (2017). Human haematopoietic stem cell lineage commitment is a continuous process. Nat. Cell Biol. 19, 271–281.
von Kleist, L., Stahlschmidt, W., Bulut, H., Gromova, K., Puchkov, D., Robertson, M.J., MacGregor, K.A., Tomilin, N., Pechstein, A., Chau, N., et al. (2011). Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 146, 471–484.
Wattacheril, J., Lavine, J.E., Chalasani, N.P., Guo, X., Kwon, S., Schwimmer, J., Molleston, J.P., Loomba, R., Brunt, E.M., Chen, Y.I., et al. (2017). Genome-Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. J. Pediatr. 190, 100–107.e102.
Wen, Q.J., Yang, Q., Goldenson, B., Malinge, S., Lasho, T., Schneider, R.K., Breyfogle, L.J., Schultz, R., Gilles, L., Koppikar, P., et al. (2015). Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat. Med. 21, 1473–1480.
Wolf, F.A., Angerer, P., and Theis, F.J. (2018). SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15.
Wolf, F.A., Hamey, F.K., Plass, M., Solana, J., Dahlin, J.S., Göttgens, B., Rajewsky, N., Simon, L., and Theis, F.J. (2019). PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. Genome Biol. 20, 59.
Wright, F.A., Strug, L.J., Doshi, V.K., Commander, C.W., Blackman, S.M., Sun, L., Berthiaume, Y., Cutler, D., Cojocaru, A., Collaco, J.M., et al. (2011). Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat. Genet. 43, 539–546.
Yamamoto, R., Morita, Y., Ooebara, J., Hamanaka, S., Onodera, M., Rudolph, K.L., Emra, H., and Nakauchi, H. (2013). Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell 154, 1112–1126.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| CD34-APC efluor780  | eBiosciences (Thermo Fisher Scientific) | Cat#47-0349-42 RRID AB_2573956 |
| CD38-PE-Texas Red   | Thermo Fisher Scientific | Cat#MHC03817 RRID AB_10392545 |
| CD90-BV421          | BioLegend | Cat#328122 RRID AB_2561420 |
| Lineage antibody cocktail (CD3, CD14, CD16, CD19, CD20, CD56)-BV510 | BioLegend | Cat#348807 |
| CD45RA-PE           | eBiosciences (Thermo Fisher Scientific) | Cat#12-0458-42 AB_10718395 |
| CD123-PE Cy7        | eBiosciences (Thermo Fisher Scientific) | Cat#25-1239-42 RRID AB_1257136 |
| CD41-APC            | eBiosciences (Thermo Fisher Scientific) | Cat#17-0419-42 RRID AB_2573144 |
| CD41a-PE            | BD     | Cat#563769 |
| CD42b-APC           | eBiosciences (Thermo Fisher Scientific) | Cat#17-0429-42 RRID AB_2573146 |
| CD36-FITC           | eBiosciences (Thermo Fisher Scientific) | Cat#11-0369-42 RRID AB_10718972 |
| CD41-PE Cy7         | eBiosciences (Thermo Fisher Scientific) | Cat#25-0419-42 RRID AB_2573348 |
| CD42b-PE            | BioLegend | Cat#303906 RRID AB_314385 |
| CD11b-APC           | eBiosciences (Thermo Fisher Scientific) | Cat#17-0118-42 RRID AB_2016659 |
| CD14-APC            | eBiosciences (Thermo Fisher Scientific) | Cat#17-0149-42 RRID AB_10669167 |
| Anti-human G6B antibody (17-4) | Prof. Yotis Senis | N/A |
| Anti-mouse IgG Alexa Fluor 488 secondary antibody | Thermo Fisher Scientific | Cat#A 10680 RRID AB_2534062 |
| CyTOF antibody cocktail | This paper | See Table S7 |
| **Biological Samples** | | |
| Peripheral blood from patients with myelofibrosis (see Tables S1 and S2) | INForMeD Study (IRAS 199833; REC 16/LO/1376 University of Oxford) Or Hammersmith Hospital Imperial College NHS Trust (R13077; 12275; REC 12/WA/0196) | ID02,ID03,ID04,ID05, ID07,ID08,ID10,ID11,ID12,ID14,ID15,ID16,ID19,ID20,ID21 |
| Peripheral blood from healthy mobilized apheresis donors (see Tables 1 and 2) | INForMeD Study (IRAS 199833; REC 16/LO/1376 University of Oxford) Or Hammersmith Hospital Imperial College NHS Trust (R13077; 12275; REC 12/WA/0196) | ID01,ID06,ID09,ID13, ID17,ID18 |
| **Chemicals, Peptides, and Recombinant Proteins** | | |
| Recombinant human thrombopoietin | PeproTech | Cat#300-18 |
| Recombinant human stem cell Factor | PeproTech | Cat#300-07 |
| Recombinant human erythropoietin | R&D Systems | Cat#287-TC-500 |
| Recombinant human IL3 | PeproTech | Cat#200-34 |
| Recombinant human IL6 | PeproTech | Cat#200-06 |
| Recombinant human GMCSF | PeproTech | Cat#300-03 |
| Recombinant human G-CSF | PeproTech | Cat#300-23 |
| May Grunewald solution | Sigma-Aldrich Inc. (Merck KGaA) | Cat#63590 |
| Giemsa stain | Sigma-Aldrich Inc. (Merck KGaA) | Cat#48900 |
| Maxpar PBS Buffer | Fluidigm | Cat#201058 |
| Maxpar Cell-ID Cisplatin Viability Stain | Fluidigm | Cat#201064 |
| Maxpar Cell Staining Buffer (CSB) | Fluidigm | Cat#201068 |
| Maxpar Nuclear Antigen Staining Buffer | Fluidigm | Cat#201063 |

(Continued on next page)
### Critical Commercial Assays

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Barcode Perm Buffer** | Fluidigm | Cat#201057 |
| **Cell-ID 20-Plex Pd Barcoding Kit** (Palladium Barcodes) | Fluidigm | Cat#201060 |
| **Nuclear Antigen Staining Perm Buffer** (NP Buffer) | Fluidigm | Cat#201063 |
| **Cell-ID Intercalator-Ir** | Fluidigm | Cat#201192A |
| **Maxpar Fx and Perm Buffer** | Fluidigm | Cat#201067 |
| **EQ Four Element Calibration Beads** | Fluidigm | Cat#201078 |
| **Cell Conditioning 2 (CC2) antigen retrieval** | F. Hoffmann-La Roche Ltd. | Cat#950-123 |
| **Ventana DISCOVERY antibody diluent** | F. Hoffmann-La Roche Ltd. | Cat#760-108 |

### Deposited Data

| DEPOSITED DATA | SOURCE |
|----------------|--------|
| 10X single cell-seq data in this manuscript | This manuscript |
| TARGET-Seq data | Rodriguez-Meira et al., 2019 |

### Experimental Models: Cell Lines

| EXPERIMENTAL MODELS: CELL LINES | SOURCE |
|----------------------------------|--------|
| HEL(human erythroleukemia) | ATCC |
| JURKAT | ATCC |
| K562 | ATCC |
| HEK | ATCC |
| HL-60 | ATCC |
| MARIMO | ATCC |
| SET-2 | Laboratory of Prof. Jacqueline Boultwood |

### Oligonucleotides

| OLIGONUCLEOTIDES | SOURCE |
|------------------|--------|
| JAK2_WT_VIC sequence VIC TCTCCAC AGACACATAC MGBNFQ | Moliterno et al., 2006 |
| JAK2V617F_MUT_FAM sequence 6FAM TCCACAGAAGACTAC MGBNFQ | Moliterno et al., 2006 |

(Continued on next page)
LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources or materials will be fulfilled by bethan.psaila@ndcls.ox.ac.uk or adam.mead@imm.ox.ac.uk.

Cell lines
HEL, JURKAT, K562, HEK, HL60 and MARIMO cells were obtained from the American Type Culture Collection (ATCC). SET-2 cells were kindly provided by Dr. Jacqueline Boultwood and Dr. Andrea Pellagatti (Radcliffe Department of Medicine, University of Oxford). All cells were maintained in culture in RPMI-1630 supplemented with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin. SET-2 cells were supplemented with 20% FCS.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

A summary of demographic and clinical details of myelofibrosis patients and normal donors used for analysis can be found in Tables S1 and S2.

METHOD DETAILS

Banking and processing of human samples
Patients and normal donors provided written informed consent in accordance with the Declaration of Helsinki for sample collection, tissue banking and use in research under either the INForMed Study, University of Oxford (IRAS: 199833; REC 16/LO/1376) or Imperial College London (approval reference: R13077; HTA license 12275; REC 12/WA/0196). Cryopreserved peripheral blood mononuclear cells stored in FCS with 10% DMSO were thawed and processed by warming briefly at 37°C, gradual dilution into RPMI-1630 supplemented with 10% FCS and 0.1mg/mL DNase I, centrifuged at 500G for 5 minutes and washed in FACS buffer (PBS + 2mM EDTA + 10% FCS).
**Fluorescent activated cell sorting (FACS) staining, analysis and cell isolation**

FACS-sorting was performed using a Becton Dickinson Aria III or Fusion 2 and cells isolated into 1.5ml Eppendorf tubes or 96-well plates depending on the experiment. Single color stained controls and fluorescence minus one (FMO) controls were used for all experiments. HSPCs were stained with the following antibody cocktail (see Key Resources Table) for 20 minutes at 4°C and passed through a 70 μm mesh cell strainer if necessary prior to sorting: CD34-APC-efluor780; Lineage-BV510; CD38-PE-TxRed; CD123-PeCy7; CD45RA-PE; CD71-AF700; CD41-APC; CD90-BV421. The following antibody cocktail was used to analyze cell differentiation: CD34-APC-efluor780, CD71-AF700, CD38-FITC, CD41 PeCy7, CD42 PE, CD11b-APC, CD14-APC. 7AAD was used for live/dead cell exclusion. For G6B immunostaining, cells were stained with anti-human G6B (17-4) for 30 minutes at 4°C (1:100), washed and stained with goat anti-mouse Alexa Fluor 488 secondary IgG antibody (2:200 ThermoFisher Cat#A10680) for 20 minutes in the fridge and washed prior to staining with fluorescence-conjugated commercial antibodies.

**In vitro liquid culture differentiation assays**

Cells were isolated by FACS into 1.5 μL eppendorfs, centrifuged at 500G for 5 minutes, resuspended in 100μl culture medium and plated in flat-bottom 96-well plates (Corning). Media used was Stemspan SFEM (StemCell Technologies #09650) + 1% Pen/Strep supplemented with the following cytokines (see also Key Resources)

| Lineage culture                  | Cytokine   | Concentration |
|----------------------------------|------------|---------------|
| Megakaryocyte single lineage     | rhTPO      | 100ng/ml      |
|                                  | rhSCF      | 50ng/ml       |
| Erythroid single lineage         | EPO        | 1U/ml increasing to 3U/ml from day 6 |
|                                  | IL3        | 10ng/ml       |
|                                  | IL6        | 20ng/ml       |
|                                  | SCF        | 100ng/ml      |
| Myeloid single lineage           | SCF        | 100ng/ml      |
|                                  | G-CSF      | 20ng/ml       |
|                                  | GM-CSF     | 20ng/ml       |
| Bi-potent Ery-MK                 | EPO        | 1U/ml         |
|                                  | TPO        | 100ng/ml      |
|                                  | SCF        | 100ng/ml      |
|                                  | IL3        | 10ng/ml       |
|                                  | IL6        | 20ng/ml       |

Cells were analyzed by FACS on days 6 and 14 (50 μL removed from wells for analysis and replaced with fresh media).

**Cytospins and MGG**

Cells were FACS-isolated into 1.5ml Eppendorf tubes, centrifuged and resuspended into 200 μL PBS and cytospun at 500RPM for 5 minutes onto Superfrost glass slides. May Grunewald Giemsa stain was prepared as per manufacturers protocol, filtered and slides stained in May–Grunewald for 7 minutes followed by 20 minutes in Giemsa then washed in distilled water, air-dried and coverslip applied.

**Methocult assay**

Single cells were FACS-isolated into flat bottomed 96-well plates containing 100 μL of MethoCult™ H4435 Enriched (StemCell Technologies Cat#04435). Colonies were visually inspected and classified 11-14 days after plating. Lineage assignment was made by morphological assessment with verification of ambiguous colonies by plucking and FACS analysis.

**High-throughput single-cell RNA-sequencing (10x Chromium)**

Cells were thawed, stained with FACS antibodies and sorted on a BD Aria III or Fusion 2 as described above and as per recommendations in the 10x Genomics Single Cell Protocols – Cell Preparation Guide. 15,000 CD34+ lineage negative cells were sorted into 2 μL PBS/0.05% BSA (non-acetylated) and then the cell number/volume adjusted to the target for loading onto the 10x Chromium Controller. Samples were processed according to the 10x protocol using the Chromium Single Cell 3’ library and Gel Bead Kits v2 (batch 1) or v3 (batch 2) (10x Genomics). Cells and reagents were prepared and loaded onto the chip and into the Chromium Controller for droplet generation. RT was conducted in the droplets and cDNA recovered through demulsification and bead purification. Pre-amplified cDNA was used for library preparation, multiplexed and sequenced on a HiSeq 2500 (batch 1) or a Novaseq.
S4 (batch 2) aiming to obtain > 50,000 reads per cell. For some samples, a preliminary, low-depth run was done on a MiSeq using MiSeq Nano Reagent Kit V2 (Illumina Cat#102-2001) to estimate the number of cells and total sequencing required.

**TARGET-seq analysis**

The count matrix for 8 myelofibrosis patients and two healthy donors profiled using 3'TARGET-seq were downloaded from GSE122198, normalized by library size and log2-transformed as previously described (Rodriguez-Meira et al., 2019). Cells were classified into WT-normal (cells from normal donors), WT-patient (non-mutant cells present in patient samples) and mutant (cells from patient samples carrying mutations in the genes targeted).

**RNA sequencing of ‘mini-bulk’ HSPC populations**

100 cells from each population were isolated by FACS into 4 μL of lysis buffer containing oligo-dT primer and dNTP mix in 0.2 mL PCR tubes. Cell lysis, RT and PCR preamplification and purification was performed using the Smart-Seq 2 protocol as previously published (Picelli et al., 2014). Libraries were pooled and tagmentation performed using the Illumina Nextera XT DNA sample preparation kit (Illumina Cat #FC-131-1024), libraries pooled and sequenced on a HiSeq 2000.

**Antibody labeling with metal conjugates and mass cytometry (CyTOF)**

Antibodies were purchased pre-conjugated when commercially available. Non-available antibodies were conjugated to lanthanide metals using Maxpar X8 antibody labeling kit according to the manufacturer protocol (version 10). The antibody cocktail used is listed in Table S7. For barcoding and staining, cells were washed with Maxpar PBS buffer (Fluidigm #201058) and stained with 0.5 μM Cell-ID Cisplatin Viability Stain (Fluidigm #201064) in 200 μL Maxpar PBS for 5 minutes at room temperature for dead cell exclusion. The reaction was quenched with Maxpar Cell Staining Buffer (CSB, Fluidigm #201063) and cells fixed, permeabilized and barcoded using the Cell-ID 20-Plex Pd Barcoding Kit (Fluidigm #201060) as per the manufacturers user guide. Barcoded cells were washed, combined and stained with the antibody cocktails as per Table S7 for 30 minutes at room temperature. Cells were washed with Maxpar Cell Staining Buffer (Fluidigm #201068), fixed in 1.6% formaldehyde, washed and resuspended in Fix&Perm Buffer (Fluidigm Cat#201067) with Cell-ID intercalator-Ir (Fluidigm #201103B) and incubated overnight at 4°C. The following day, cells were washed and analyzed on a Helios (Fluidigm). The mass cytometer was tuned and QC was run prior to acquiring samples according to the manufacturers’ recommendations.

**G6B Immunohistochemistry**

Sections of formalin fixed and paraffin embedded (FFPE) bone marrow trephine biopsies were processed as follows: paraffin was removed, then antigen retrieval was performed using citrate (Roche Cell Conditioning 2 Cat#950-123) pre-treatment for 30 minutes. Sections were washed and incubated with G6B antibody diluted 1:100 in Ventana’s DISCOVERY antibody diluent (Roche Cat#760-108) for 60 minutes at room temperature. Secondary detection was performed using UltraMap DAB anti-Ms HRP detection kit (Roche #760-152) for 16 minutes and slides counterstained with hematoxylin (Roche #760-2021) for 4 minutes and Bluing reagent (Roche #760-2037) for 4 minutes.

**Sorting G6B+ and G6B- HSPCs for JAK2V617F qRT-PCR**

For each experiment, MNCs from myelofibrosis patients and healthy donor controls were thawed and combined 1:1 in FACS buffer prior to antibody staining as described above. 50 G6B+ and G6B- cells were sorted into each well of a 96-well PCR plate (10 replicates per population for each experiment), containing CellsDirect One-Step qRT-PCR kit 2X Reaction Buffer and SuperScript III RT/Platinum Taq Mix (Thermo Fisher Cat#11753100), Ambion SUPERase-In RNase inhibitor (Thermo Fisher Cat#AM2694), TE buffer, JAK2 forward and reverse primers and wild-type and JAK2V617F-specific probe mix (see Key Resources Table). RT and PCR were performed as per manufacturer’s recommendations with 18 pre-amplification cycles and then diluted 5x in TE buffer. Taqman RT-PCR was performed in a 20 μL reaction volume using 4 μL of the diluted cDNA, Taqman Fast Advance Mastermix (Thermo Fisher Cat#4444556) and the primers/probes as detailed in the Key Resources Table. Custom Taqman assays were designed (see Key Resources Table) as previously described (Moliterno et al., 2006) using RT-PCR primers flanking the mutant region plus two Taqman PCR probes specific for the normal or mutant sequence. An Applied Biosystems 7500 Fast Real-Time PCR system was used with the default PCR conditions, with each replicate run in duplicate. Intra-assay replicates varying more than 5% were excluded.

**CD34 x G6B bispecific antibody generation**

The CD34 x G6B bispecific antibody contains a human IgG1 Fc and was produced using ‘knobs-into-holes’ technology, which involves generating a single amino acid substitution in opposite CH3 domains (Ridgway et al., 1996). Each sequence was inserted into the pcDNA 3.4 expression vector (Thermo Fisher). Following preparation of plasmid DNA, each chain was co-transfected into Chinese Hamster Ovarian cells at a 200 mL scale using the ExpiCHO expression system (Thermo Fisher). The Max Titer protocol was followed. Cells were incubated in a 37°C incubator with a humidified atmosphere of 8% CO2 in air on an orbital shaker. On the day after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed was added to the flask at the appropriate volume and the flask was transferred to a 32C incubator with a humidified atmosphere of 5% CO2 in air on an orbital shaker. On Day 5 post-transfection, the
second volume of ExpICHO Feed was added to the flask. On Day 14, the cells were harvested by centrifuging at 18,000 g for 30 min. The protein was purified from the supernatant using protein A affinity resin (GE HealthCare Life Sciences). Bound protein was eluted with 20 mM Citrate at pH 2.9 and then immediately neutralized with 10% 1 M Tris. The protein was then further purified using size exclusion chromatography (SEC), and characterized by SDS-PAGE gel and analytical scale SEC.

**Antibody internalization experiments**

The CD34 × G6B bispecific and a non-targeting isotype control (DNP-MB273, Acrobiosystems) were conjugated to Cypher5E (GE Healthcare Life Sciences), a red-excitable, pH-sensitive cyanine dye detected in the APC or Ax647 channel that maximally fluoresces at an acidic pH (i.e., after movement from a receptor on the cell surface to acidic endosomes upon internalization). HEL and SET-2 cells were re-suspended in serum-free, no phenol red RPMI and incubated with DMSO or inhibitors for 30 minutes at 37°C, 5% CO2 prior to the addition of either the CD34 × G6B bispecific or isotype control (5 μg/ml), followed by a further incubation for 30 minutes at 37°C, 5% CO2. For flow cytometry, cells were then washed twice with PBS and re-suspended in PBS for flow analysis on a Beckman Flow CytoFLEX cytometer. For live cell imaging, cells were plated onto slides with flat wells (Hendley-Essex) and imaged on a Zeiss inverted confocal LSM870 with an apochromatic 40X oil immersion objective lens. Two inhibitors were used - Dynasore, a GTPase inhibitor of dynamin (Sigma) (Macia et al., 2006) at 100 μM and Pitstop 2 (Sigma) (von Kleist et al., 2011) at 30 μM concentration, that inhibits the clathrin terminal domain as well as clathrin-independent endocytosis.

**10x Genomics single-cell RNA sequencing data pre-processing and integration**

Sequencing data in the binary base call (BCL) format were demultiplexed. Unique molecular identifier (UMI) counts were obtained by aligning FASTQ files to the human reference genome (GRCh38 3.0.0) using Cell Ranger software (version 3.0.1) from 10x Genomics. The CellRanger “count” standard pipeline was used to obtain the expression matrix for each individual library for each donor. Cells meeting the following QC parameters (detailed in Table S3) were included in analyses: UMI counts > 1,000 and ≤ maximum UMIs; number of detected genes > 500 and ≤ maximum number of detected genes); the percentage of mitochondrial gene expression < 15% per cell. Genes expressed in at least 10 cells were included. Following application of these filters, 122,154 cells passed quality control (83,753 cells from myelofibrosis patients and 38,401 cells from healthy donors, see Table S3). We scaled UMI counts by normalizing each library size to 10000. The normalized expression values were then log transformed (Ritchie et al., 2015).

**Dimensionality reduction, removal of individual donor effect and cell clustering**

Sparse expression matrices of cells obtaining from the CellRanger output for individual donor were combined. Highly variable genes were identified by fitting mean expression values and the squared coefficient of variation (CV^2) calculated with a gamma generalized linear model using the “glmGamFit” function in the statmod package in R as described previously (Brennecke et al., 2013). Using a mean expression value of > 0.05 and the dispersion score of > 0.05, 800 genes were identified as highly variable genes. 12 ribosomal, mitochondrial and heat shock protein genes were removed (Kampinga et al., 2009; Nakao et al., 2004), resulting in 788 highly variable genes being used for down-stream analysis. Donor effect was regressed out using Combat from the sva package (Johnson et al., 2007) by regressing out on the donor IDs. Following this, there was no clear batch effect in the dataset (Figure S1C). Principal Component Analysis (PCA) was then performed on normalized expression values on the first 50 principal components (PCs). An elbow plot was inspected to determine the appropriate number of top PCs capturing the most of variances. Using this approach, we selected the first 20 PCs for further analyses. Uniform Manifold Approximation and Projection (UMAP) analysis was performed using the “uwot” function on the embedded matrix derived from the first 20 PCs and 30 neighbors using cosine as the metric parameter. Cells were clustered using the k-nearest neighbor (KNN) approach, using Euclidean metric as the input parameter. The weighted graph was created with the weight values calculated from the normalized shared number of the nearest neighbors. The function ‘cluster_louvain’ from the igraph package (Csardi and Nepusz, 2005) was then applied to identify clusters based on the weighted graph. Identified clusters were superimposed on the two-dimensional UMAP. We identified a distinct cluster (n = 1,958 cells) expressing a gene signature corresponding to plasmacytoid dendritic cells (pDC) (Figure S1D) and we removed this cluster from further analyses as they are not hematopoietic stem/progenitor cells but contaminating mature cells that fall into the CD34+Lin- FACS gate. After removing the pDC cluster, 120,196 cells (82,255 from myelofibrosis donors and 37,941 cells from healthy donors) from all 21 donors (myelofibrosis patients + controls) were included in analyses. Highly variable genes were recalculated, and 817 were identified; 12 of which were removed (heat-shock/mitochondrial/ribosomal genes), resulting in 805 highly variable genes being used for all downstream analyses. Eighteen clusters were initially identified, differentially expressed genes inspected and clusters with similar profiles were merged. This resulted in eight major clusters representing HSPC and lineage progenitor populations, as shown in Figures 2A and 2B.

**Lineage signature gene sets**

Lineage signature gene sets were collated by curating known canonical lineage markers selected from multiple recently published hematopoiesis datasets (Buenrostro et al., 2018; Hua et al., 2019; Pellin et al., 2019; Popescu et al., 2019). Genes selectively expressed in hematopoietic lineage progenitors and uncommitted HSPCs were identified (see Table S5). Expression of each gene was plotted individually on the UMAP plot and genes that were highly expressed and most specifically marked distinct lineage clusters or uncommitted HSPCs in the HSPC UMAP were selected for inclusion in the ‘signature gene sets’ (see Figure S2). These gene sets or uncommitted HSPCs in the HSPC UMAP were selected for inclusion in the ‘signature gene sets’ (see Figure S2). These gene sets
sets were used to calculate a ‘lineage gene score’ for each cell, based on the average gene expression of each lineage gene set. These scores were superimposed on the UMAP and FDG plots (Figures 2B and 3).

**Marker gene identification and cell type annotation**

Differentially expressed genes for each cluster were identified using the nonparametric Wilcoxon test on the log-transformed, normalized UMI values to compare expression level. Fisher’s exact test was used to compare the cell frequency expressing each gene as previously described (Giustacchini et al., 2017). P values generated from both tests were then combined using Fisher’s method and were adjusted using the Benjamini-Hochberg (BH) correction. Genes expressed by each individual cluster were compared to all other clusters and differential expression defined as an absolute log2 fold change of ≥ 0.5 and adjusted P value of < 0.05, with the fraction of expressing cell frequency of > 0.3. Differentially expressed genes were ranked using P values and log2FC to select up to 50 genes per cluster (Tables S4 and S6). Clusters were identified by manual inspection of differentially expressed genes for canonical marker genes of blood cell lineages. All heatmaps show scaled (z-score) expression values.

**Down-sampling of myelofibrosis cells**

To generate a dataset with equal numbers of myelofibrosis and control cells, myelofibrosis cells were ‘down-sampled’ to 37,941 cells. This number is equal to the maximum number of cells that passed QC in the healthy control. These cells were integrated with all the cells from healthy donors, and analyses from normalization to clustering as described above were repeated. 722 highly variable genes were detected and 12 ribosomal, mitochondrial and heat shock protein genes were removed, resulting in 710 highly variable genes used for subsequent analyses. Seventeen clusters were identified initially, clusters expressing erythroid, megakaryocyte, myeloid and lymphoid genes signatures were merged (Figure S1 F). The percentage of cells in each of these lineage clusters from each donor type was quantified (Figure 2D).

**MkP identification and sub-clustering analysis**

Using the same method as described above, cells from the two donor types (healthy donor controls and myelofibrosis patients) were integrated separately. 847 and 680 highly variable genes were detected and 18 and 14 clusters for the MF and control respectively. As shown in Figure S4A, clusters 8, 13, 14, 15, and 16 (n = 8134 cells) were identified as MkP clusters in the myelofibrosis UMAP and clusters 13 and 14 (n = 141 cells) in the healthy donor UMAP. We used the AUCell package (Albar et al., 2017) to calculate the AUCell score for megakaryocyte signature genes for each individual cell within these clusters. Based on the score distribution, we selected AUCell score > 0.4 (Figure S4A) to define MkP. This resulted in 4,134 and 139 MkP cells being identified from myelofibrosis and healthy control donors respectively. To examine the heterogeneity among myelofibrosis MkP, normalization and clustering were performed as described above. 20 PCs were used for analysis and 1195 highly variable genes were identified after removing 11 ribosomal, mitochondrial, and heatshock protein genes. Clustering analysis revealed 9 sub-clusters of myelofibrosis MkP (Figure 5D).

**Individual donor analysis**

After removing plasmacytoid dendritic cells for each individual, a standard pipeline described above was used. 20 PCs and 30 neighbors were used for UMAP and clustering analyses. 20 PCs and 5 neighbors were used for the force-directed graph (FDG) analysis (Figure S3).

**Differentiation trajectory analysis**

ForceAtlas2 software (Jacomy et al., 2014) was used to visualize differentiation trajectories over the force-directed graph layout. The KNN weighted graph was used as the input for the software, and analysis performed with the following parameters: iterations = 1,000, edgeWeightInfluence = 1, barnesHutTheta = 2, scalingRatio = 1, gravity = 0.05 and jitterTolerance = 1. The output layout was plotted using ggplot2 and superimposed with normalized lineage signature gene scores (average expression values) for myeloid, erythroid, lymphoid and megakaryocyte lineages (Table S5). Transparent factors for selected colors were calculated from normalized expression values across cell types. ggplot2 was used, adding the dynamic alpha parameter values to “geom_point” to control the transparency of colors as shown in Figures 3A, 3B, and 3C.

To identify the differentiation paths, the PAGA function in the Scanpy toolkit was used (Wolf et al., 2018, 2019). Clusters were identified using canonical lineage marker genes as hematopoietic stem cell (HSC), hematopoietic stem/progenitor cell (HSPC1, HSPC2, HSPC3), erythroid (Ery), megakaryocyte (Mega) and myeloid (Mye) (Figure 4A), with HSC clearly positioned at the root of the trajectory. As shown in Figures 4A and 4B, the predominant path for megakaryocyte differentiation was HSC → HSPC2 → Mk.

Scanpy (version 1.4.5) was used for UMAP, FDG, and diffusion maps analyses (Figure S3D) to compare the results of our in-house analysis pipeline with the existing analysis tool. The ‘sc.pp.combat’ function in scanpy was used to correct donor effect by regression out donor IDs. The ‘sc.pp.highly_variable_genes’ function was used by setting ‘n_top_genes’ to the same number of genes used in the in-house pipeline. 20 PCs and 30 neighbors were used to run UMAP, diffusion map, and FDG functions. Megakaryocyte signature genes (Table S5) were superimposed on the UMAP, diffusion map and FDG.
Identifying patterns of expression of transcription factor genes along megakaryocyte and erythroid trajectories in myelofibrosis patients

To examine expression of 1,639 transcriptional factors (Lambert et al., 2018) along the megakaryocyte and erythroid differentiation trajectories, the 82,255 myelofibrosis HSPCs were clustered by the Louvain community-detection method (resolution = 0.5). Seven major clusters were identified and projected on the FDG layout using Scanpy. Differentially expressed genes for each cluster were identified as described above. 16 transcription factor genes showing progressive changes, either increased or decreased expression, along the two trajectories were selected (Figures 4B and 4C).

The heatmap was generated by calculating the running average of the gene expression for cells along the path using the function ‘scanpy.pl.paga_path’ in Scanpy to investigate dynamic changes in gene expression. The n.avg parameter was set at 5000 for the number of data points to include in the computation of the running average, to ensure a smooth transition.

GeneSet Enrichment Analysis
GSEA was performed using GSEA software (https://www.gsea-msigdb.org/gsea/index.jsp) with ‘Run GSEAPreranked’ and default parameters. The HALLMARK gene set used for the analysis was downloaded from MSigDB (https://www.broadinstitute.org/gsea/msigdb/collections.jsp). 9,313 expressed genes were used for the analysis. Genes were pre-ranked in order of their differential expression between myelofibrosis and healthy donor megakaryocyte progenitors. The Pathways with FDR q-value < 0.25 were selected showing in Figure 5B.

Integration of 10x Genomics and TARGET-seq datasets
37,941 cells (the down-sampled dataset) from 15 myelofibrosis patients processed using the Chromium platform (10x Genomics) and 2,071 cells from 8 myelofibrosis patients (obtained from Rodriguez-Meira et al., 2019; GSE122198) were projected into a shared embedding with Harmony (Korsunsky et al., 2019), using the top 20 PCA dimensions. The effect of the platform (10X Genomics/TARGET-seq) and donor were simultaneously accounted for and introduced as covariates. Then, dimensionality reduction and force directed graph analysis were performed as described above (Dimensionality reduction, removal of individual donor effect and cell clustering). To quantify the proportion of mutant and wild-type cells in each lineage progenitor cluster, clusters were identified by inspection of differentially expressed genes and super-imposition of the lineage gene set scores on the UMAP and FDG graphs as described above, and mutant and wild-type cells enumerated for myeloid, erythroid and megakaryocyte progenitor clusters. Proportions of wild-type and mutant cells for each of cluster pair were compared using a Chi-square test (p value) with Yates’ continuity correction.

QUANTIFICATION AND STATISTICAL ANALYSIS

Flow cytometry and CyTOF data analysis
Flow cytometry data was analyzed using FlowJo software (v10.5.3). Summary charts and associated statistical analyses were performed using GraphPad Prism (v6.1.0). Helios CyTOF Software (v6.7) was used for processing of FCS 3.0 files, normalization to EQ Beads, concatenation of multiple files and debarcoding. Data was then analyzed and histograms and viSNE plots generated using CytoBank.org.

Statistical tests used, numbers of replicates and definitions of statistical significance are described in the relevant figure legends. All bar charts show mean ± standard error of the mean and were generated using GraphPad Prism (v.8.1.0).

To compare the proportions of wild-type versus mutant cells in lineage progenitor clusters (Figure S6A), Fisher’s exact test was used. To compare the expression of key genes in different sub-clones within the same patients (Figures 6B, 6C, and S6B), Fisher’s test was used to compare the expression frequencies between the groups and Wilcoxon rank sum test to compare the expression levels. P values were combined using Fisher’s method, and the combined p value for each pairwise comparison are reported in Figure S6.

DATA AND CODE AVAILABILITY

10x Genomics single cell RNA-sequencing data has been submitted to GEO database (Accession Number GEO: GSE144568). TARGET-seq single cell RNA-sequencing data is available at Accession Number GEO: GSE122198. The Shiny application for visualization of the data from patients and healthy donors in this study is available at https://github.com/supatt-lab/SingCellaR-myelofibrosis. R scripts used for the analysis are available upon request.
Supplemental Information

Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets

Bethan Psaila, Guanlin Wang, Alba Rodriguez-Meira, Rong Li, Elisabeth F. Heuston, Lauren Murphy, Daniel Yee, Ian S. Hitchcock, Nikolaos Sousos, Jennifer O'Sullivan, Stacie Anderson, Yotis A. Senis, Olga K. Weinberg, Monica L. Calicchio, NIH Intramural Sequencing Center, Deena Iskander, Daniel Royston, Dragana Milojkovic, Irene Roberts, David M. Bodine, Supat Thongjuea, and Adam J. Mead
SUPPLEMENTAL ITEMS (Psaila et al)

Supplemental Figure Legends

Suppl. Figure 1, Relating to Figures 1-7 and methods. Isolation and characterization of CD41+ and CD41- HSPCs, integration of scRNAseq data from individual donors and cell cluster identification. **S1A.** Lin^-CD34^-CD38^-CD45RA^-CD41+ (CD41+ HSC/MPP) and Lin^-CD34^-CD38^-CD45RA^-CD41+ (CD41+ CMP/MEP) compartments contain cells with typical blast cell morphology and not mature megakaryocytes. Cells were isolated by FACS and stained with May Grunewald Giemsa, representative cells shown (200X magnification). **S1B.** Single-cell colony output from control and myelofibrosis CD41- HSC, CD41-MPP and CD41+ HSC/MPP cells FACS-isolated into individual wells of 96-well plates containing methylcellulose. Total colonies counted = 250 sorted from healthy control (n=5) and myelofibrosis (n=6) donors. Abbreviations: CFU – colony-forming unit; GM – granulocyte-monocyte; E – erythroid; GEMM – granulocyte-erythroid-monocyte-megakaryocyte. * - P<0.05 for CFU-GM output of control vs. myelofibrosis CD41- MPP; all other comparisons non-significant. **S1C:** All 122,154 cells were aggregated from the 21 individual donors, with good integration of samples and batches after individual donor effect was regressed out. Left plot - cells are colored by donor ID; right plot – cells colored by batch. **S1D:** A cluster of cells expressing high levels of plasmacytoid dendritic cell markers GZMB, EPHA2 and PPM1J was identified and removed from downstream analyses, as these are mature lymphoid cells and not hematopoietic stem/progenitor cells. **S1E:** Marker genes for the 8 identified clusters in the UMAP aggregate of all cells. **S1F:** Myelofibrosis cells were down-sampled to generate an aggregate that contained equal numbers of myelofibrosis and control cells (37,941 cells of each). Left plot – distribution of cells by disease (myelofibrosis – red; controls – blue); middle – superimposition of lineage signature genes (Suppl. Table 5); right – lineage progenitor clusters (Mk – megakaryocyte; Lymph – lymphoid; Ery – erythroid; Mye – myeloid), relating to Fig. 2D.

Suppl. Fig. 2, relating to Figures 2 and 3 and Suppl. Table 5. Expression of individual genes comprising lineage signature gene sets. Cells on Uniform Manifold Approximation and Projection (UMAP) plots are colored according to expression levels of each gene used in the respective lineage progenitor ‘gene signature’ set. Abbreviations: HSPC - hematopoietic stem/progenitor cells; Ery – erythroid; Lym – lymphoid; Mega – megakaryocyte; Mye – myeloid.

Suppl. Fig. 3, Relating to Figures 2 and 3. Force-directed trajectory graphs (FDG) for individual donors and comparison of FDG and diffusion map trajectory analyses. **S3A:** Patients with
JAK2V617F-mutated myelofibrosis (n=12); S3B: Patients with CALR-mutated myelofibrosis (n=3); S3C: Healthy donor controls (n=6). Diagnosis (primary or secondary myelofibrosis) and treatment at time of analysis are shown (PPV MF – post polycythemia vera myelofibrosis; PET MF – post essential thrombocytemia myelofibrosis; PMF – primary myelofibrosis; Hydroxy – hydroxycarbamide; No Tx – no treatment; Rux – ruxolitinib. S3D: Differentiation trajectory plots generated using Scanpy confirms presence of substantially augmented megakaryocyte differentiation trajectory as seen in FDG (Fig. 3) generated using in-house pipeline. Left plots – UMAP; middle – FDG, Right – diffusion maps. Arrow indicates megakaryocyte trajectory in each plot.

Suppl. Fig. 4, Relating to Fig. 5. Identification and comparison of myelofibrosis and control megakaryocyte progenitors (MkP). S4A: UMAP plots of control (top row) and myelofibrosis (MF, bottom row) HSPCs. Far left – expression of lineage gene scores; Left – identified clusters; Right – cells with an AUCell score for Mk genes >0.4; Far right – overlap, i.e. all cells from clusters with a Mk gene expression signature (clusters 8, 13, 14, 15, 16 for MF and 13 and 14 for controls) that had an AUCell score > 0.4. S4B: Heatmap of all differentially expressed genes (n=3,496) demonstrating that the majority of control MkP have a similar transcriptional profile to one sub-cluster of myelofibrosis MkP, while a larger unique population of MF MkP was detected with overall upregulation of gene expression.

Suppl. Fig. 5, relating to Fig. 5. Marker genes for myelofibrosis megakaryocyte progenitor sub-clusters and cell cycle genes. S5A: Heatmap showing 6 differentially expressed genes for each of the myelofibrosis MkP sub-clusters. S5B: Expression of G2M and S-phase genes on the myelofibrosis HSPC (left) and MkP (right) UMAPs. S5C: Expression of MKI67 in the UMAPS for myelofibrosis (left) and control (right) HSPCs.

Suppl. Fig. 6, Relating to Figure 6. Trajectory analysis of the integrated dataset of cells analysed by 10x Genomics and TARGET-seq (simultaneous mutation detection and scRNAseq) and G6B expression within distinct molecular sub-clones. S6A: Top left: Force directed graph (FDG) showing integration of cells analysed by 10x Genomics and TARGET-seq; Top right: FDG with lineage gene signature scores overlaid; lower left: unsupervised cell clustering (Louvain); lower right: cells analysed by TARGET-seq identified by genotypte (wild-type and mutant); chart shows percentage of wild-type and mutant cells in the louvain clusters corresponding to the lineage progenitors (myeloid – cluster 7; megakaryocyte (MK) – cluster 4; erythroid – cluster 3). P-values shown for Fisher’s exact test for relevant pair-wise comparison (* - P<0.05; *** - P<0.001). S6B: Expression of G6B is detected.
in all genetic subclones in two myelofibrosis patients with 3 or more genetic subclones. x-axis – number of cells in which G6B expression was detected out of all cells of each genetic subclone identified. All pair-wise comparisons non-significant (Fisher’s Exact Test).

**Suppl. Fig. 7, Relating to Figure 7. Expression and targeting of G6B in JAK2V617F-mutated MPN cell lines and other leukemic cell lines. S7A:** Expression and frequency of selected cell surface markers in MARIMO (mutCALR acute myeloid leukemia), HL60 (acute myeloid leukemia), JURKAT (T-cell leukemia), K562 (chronic myeloid leukemia), or human embryonic kidney HEK cells measured by CyTOF. S7B: Live cell imaging (left) and flow cytometry demonstrating internalization of CD34 x G6B bispecific in HEL cells (which are CD34−, G6B+). N=3.

**Supplemental Tables 1, 5 and 7 (Suppl. Tables 2, 3, 4 and 6 as excel files)**

**Suppl. Table 1, Relating to Figures 1-7: Clinical details of all myelofibrosis patients and healthy donor controls studied.**

Abbreviations: PMF – primary myelofibrosis; PET MF – post essential thrombocythemia myelofibrosis; PPV MF – post polycythaemia myelofibrosis; Con – healthy donor controls; Hydroxy – hydroxycarbamide; EPO – recombinant human erythropoietin. DIPPS – dynamic international prognostic scoring system (Passamonti et al., 2010).

| Study ID  | Age | Sex | Disease status | Mutations                      | Treatment       | WHO fibrosis grade in BM | DIPPS risk group |
|-----------|-----|-----|----------------|--------------------------------|-----------------|--------------------------|------------------|
| 001_001   | 70  | M   | PMF            | JAK2V617F, CBL, SRSF2         | None            | 3                        | Int-1            |
| 001_002   | 56  | M   | PET MF         | CALR type 2, U2AF1            | Ruxolitinib     | 3                        | Int-2            |
| 001_018   | 73  | M   | PPV MF         | JAK2V617F, ASXL1, ETV6        | None            | 3                        | Int-2            |
| 001_020   | 61  | M   | PET MF         | CALR type 1                   | Ruxolitinib     | 3                        | Low              |
| 001_023   | 86  | M   | PMF            | JAK2V617F, SF3B1              | Ruxolitinib     | 3                        | Int-2            |
| 001_038   | 60  | M   | PPV MF         | JAK2V617F                     | Hydroxy         | 3                        | Int-1            |
| 001_040   | 73  | F   | PPV MF         | JAK2V617F                     | Ruxolitinib     | 3                        | Int-2            |
| 001_042   | 57  | F   | PET MF         | MPL W515K                     | None            | 2-3                      | Int-1            |
| ID    | Age | Gender | Diagnosis | Mutation | Treatment | Duration | Stage |
|-------|-----|--------|-----------|----------|-----------|----------|-------|
| 001_047 | 81  | F      | PMF       | CALR type 1 | Ruxolitinib | 3        | Int-1 |
| 001_054 | 76  | F      | PET MF    | JAK2V617F, ETV6 | None (prior anagrelide) | 3        | Int-2 |
| 001_057 | 67  | F      | PPV MF    | JAK2V617F | Ruxolitinib | 2        | Int-1 |
| 001_076 | 70  | F      | PET MF    | CALR type 1 | Luspatercept | 2        | Int-1 |
| 001_098 | 58  | F      | PMF       | CALR type 2, ASXL1 | None | 2-3 | Int-1 |
| 001_102 | 72  | F      | PMF       | CALR type 1 | Pacitininib | 2        | Int-1 |
| 001_110 | 69  | M      | PPV MF    | JAK2V617F, ASXL1, EZH2 | None | 3 | Int-2 |
| 001_114 | 68  | M      | PPV MF    | JAK2V617F, ASXL1 | Hydroxy | 3 | Int-1 |
| 001_124 | 70  | M      | PMF       | JAK2V617F, ASXL1 | Ruxolitinib | 3 | Int-2 |
| 001_127 | 61  | M      | PMF       | JAK2V617F, TET2, SF3B1 | None | 3 | Int-2 |
| 001_128 | 54  | M      | PMF       | CALR Type 1-like | None | 3 | Int-1 |
| 001_131 | 49  | F      | PPV MF    | JAK2V617F | None | 2-3 | Int-1 |
| 001_132 | 75  | M      | PPV MF    | JAK2V617F | Ruxolitinib | 3 | Int-2 |
| 006_002 | 67  | F      | PMF       | JAK2V617F | Momelotinib | 3 | Int-1 |
| 010_022 | 65  | F      | PPV MF    | JAK2V617F | Hydroxy | 2 | Int-1 |
| 010_054 | 77  | M      | PPV MF    | JAK2V617F | Ruxolitinib | 3 | Int-2 |
| 010_047 | 56  | F      | PMF       | JAK2V617F | Ruxolitinib | 3 | Int-2 |
| 010_005 | 62  | M      | PMF       | JAK2V617F | Danazol | 3 | Int-2 |
| 010_027 | 72  | M      | PET MF    | JAK2V617F | Ruxolitinib and EPO | 2 | Int-2 |
| 010_028 | 74  | M      | PPV MF    | JAK2V617F | Ruxolitinib | 2 | Int-1 |
| 010_003 | 79  | M      | PPV MF    | JAK2V617F | Ruxolitinib | 3 | Int-2 |
| 010_055 | 54  | F      | PMF       | JAK2V617F | Ruxolitinib | 2 | Int-1 |
| 010_019 | 78  | M      | PET MF    | JAK2V617F | Ruxolitinib and EPO | 3 | Int-2 |
| 010_056 | 60  | M      | PMF       | JAK2V617F | None | 3 | Int-1 |
| 009_001 | 67  |       | Control   |          |           |          |       |
| 009_002 | 42  |       | Control   |          |           |          |       |
| 009_003 | 35  |       | Control   |          |           |          |       |
| 009_005 | 60  |       | Control   |          |           |          |       |
Suppl. Table 5, Relating to Figures 2, 3 and 5. Genes included in HSPC/lineage progenitor gene signatures, fibrosis signature gene sets and G2M and S phase gene sets.

| Mye  | Ery  | Lymph | Mega | HSPC | Fibrosis Signature Gene Score | G2M | S phase |
|------|------|-------|------|------|-------------------------------|-----|---------|
| ELANE | EPOR | VPREB1 | MPIG6B | CRHB | TGFB1 | HMGB2 | MCM5 |      |
| AZU1  | KLF1 | JCHAIN | PF4  | EMCN | IL12A | CDK1  | PCNA |      |
| PRTN3 | TFR2 | CD22  | GP9  | HLF  | IL15  | NUSAP1 | TYMS |      |
| CFD   | CSF2RB | IGHD | VWF  | AVP  | IL1B  | UBE2C | FEN1 |      |
| MPO   | APOE | LTB   | SELP | ACTR5 | BIRC5 | MCM2  |      |      |
| CSF1R | APOC1 |      |      | RAB37 | TPX2  | MCM4  |      |      |
| CST7  | CNRIP1 |      |      | C2orf194 | TOP2A | RRM1  |      |      |
| CTSG  |      |      |      | TOLLIP | NDC80 | UNG  |      |      |
|       |      |      |      | GOSR2 | CKS2  | GINS2 |      |      |
| TIMP1  | NUF2  | MCM6  |
|--------|-------|-------|
| APIP   | CKS1B | CDCA7 |
| RAB7B  | MKI67 | DTL   |
| PF4    | TMPO  | PRIM1 |
| VEGFA  | CENPF | UHRF1 |
| TACC3  | MLF1P |       |
| FAM64A | HELLS |
| SMC4   | RFC2  |
| CCNB2  | RPA2  |
| CKAP2L | NASP  |
| CKAP2  | RAD51AP1 |
| AURKB  | GMNN  |
| BUB1   | WDR76 |
| KIF11  | SLBP  |
| ANP32E | CCNE2 |
| TUBB4B | UBR7  |
| GTSE1  | POLD3 |
| KIF20B | MSH2  |
| HJURP  | ATAD2 |
| CDC3A  | RAD51 |
| HN1    | RRM2  |
| CDC20  | CDC45 |
| TTK    | CDC6  |
| CDC25C | EXO1  |
| KIF2C  | TIPIN |
| RANGAP1| DSCC1 |
| NCAPD2 | BLM   |
| DLGAP5 | CASP8AP2 |
| CDCA2  | USP1  |
| CDCA8  | CLSPN |
| ECT2   | POLA1 |
| KIF23  | CHAF1B |
| HMMR   | BRIP1 |
| AURKA  | E2F8  |
| PSRC1  |       |
| ANLN   |       |
| LBR    |       |
| CKAP5  |       |
| CENPE  |       |
| CTCF   |       |
| NEK2   |       |
Suppl. Table 7, Relating to Figure 7. Antibodies used for cell surface antigens in CyTOF panel.

| Marker       | Clone  | Supplier  | Catalogue number | Titration (uL/100ul) | Isotope |
|--------------|--------|-----------|------------------|----------------------|---------|
| CD41         | HIP8   | Fluidigm  | 3089004B         | 1.0                  | 89Y     |
| CD19         | SJ25-C1| Invitrogen| MHCD1906         | 0.2                  | 111Cd   |
| CD9          | HI9a   | Biolegend | 312102-227707    | 1.0                  | 142 Nd  |
| CD45RA       | HI100  | Fluidigm  | 3143006B         | 1.0                  | 143 Nd  |
| CD42b        | HIP1   | Fluidigm  | 3144020B         | 1.0                  | 144 Nd  |
| CD4          | RPA-T4 | Fluidigm  | 300502           | 0.5                  | 145 Nd  |
| CD34         | 581    | Fluidigm  | 3148001B         | 1.0                  | 148 Nd  |
| CD56         | NCAM16.3| Fluidigm  | 3149021B         | 1.0                  | 149 Sm  |
| CD123 (IL-3R)| 6H6   | Fluidigm  | 3151001B         | 1.0                  | 151 Eu  |
| CD3          | UCHT1  | Fluidigm  | 3154003B         | 0.5                  | 154 Sm  |
| CD36         | 5-271  | Fluidigm  | 3155012B         | 1.0                  | 155 Gd  |
| CD14         | M5E2   | Biolegend  | 301802           | 0.3                  | 160 Gd  |
| CD90         | 5.00E+10 | Fluidigm  | 3161009B         | 1.0                  | 161 Dy  |
| CD49f        | G0H3   | Fluidigm  | 3164006B         | 1.0                  | 164 Dy  |
| CD44         | BJ18   | Fluidigm  | 3166001B         | 1.0                  | 166 Er  |
| RXFP1        | 933344 | R&D Systems| MAB8898         | 1.0                  | 170 Er  |
| CD38         | HIT2   | Fluidigm  | 3172007B         | 1.0                  | 172 Yb  |
| CLEC2        | AYP1   | Biolegend  | 372002           | 1.0                  | 174 Yb  |
| CD71         | OKT-9  | Fluidigm  | 3175011B         | 1.0                  | 175 Lu  |
| G6B          | clone 17-4| Collaborator | NA            | 2.0                  | 176 Yb  |
S3A JAK2V617F+ (N = 12)

ID02-PPV MF Hydroxy  ID19-PPV MF Hydroxy  ID14-PPV MF Hydroxy  ID07-PPV MF No Tx  ID12-PPV MF No Tx

ID05-PPV MF No Tx  ID08-PMF No Tx  ID11-PMF Rux  ID03-PPV MF Rux  ID10-PPV MF Rux

ID20-PPV MF Rux  ID21-PPV MF Rux

S3B CALRmut (N = 3)

ID04-PMF No Tx  ID15-PMF No Tx  ID16-PMF Pacritinib

S3C healthy donors (N = 6)

ID01  ID06  ID09  ID13  ID17  ID18

S3D

Control

FDG  Diffusion Map

UMAP  FDG  Diffusion Map

UMAP  FDG  Diffusion Map
S4A

lineages

clusters

AUcell > 0.4

Overlap

Control

MF

S4B

expression

MF MkP

Control MKP
S7A

| Set2  | HEL  | Jurkat | K562 | HEK | HL60 | MARIMO |
|-------|------|--------|------|-----|------|--------|
| 89Y_CD41 | 176Yb_G6B | 174b_CLEC2 | 144Nd_CD42 | 155Gd_CD36 | 142Nd_CD9 | 175Lu_CD71 |

S7B

HEL cells +/- inhibitor (0.5 h)

- CD34 x G6B-CypHer5E
- Isotype-CypHer5E

DMSO, Dynasore, Pitstop 2